<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Pflugers Arch</journal-id><journal-id journal-id-type="iso-abbrev">Pflugers Arch</journal-id><journal-title-group><journal-title>Pflugers Archiv</journal-title></journal-title-group><issn pub-type="ppub">0031-6768</issn><issn pub-type="epub">1432-2013</issn><publisher><publisher-name>Springer Berlin Heidelberg</publisher-name><publisher-loc>Berlin/Heidelberg</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">39899071</article-id><article-id pub-id-type="pmc">PMC12092484</article-id>
<article-id pub-id-type="publisher-id">3068</article-id><article-id pub-id-type="doi">10.1007/s00424-025-03068-6</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Sphingosine kinase 1 inhibition aggravates vascular smooth muscle cell calcification</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Razazian</surname><given-names>Mehdi</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Bahiraii</surname><given-names>Sheyda</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Jannat</surname><given-names>Isratul</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Tiffner</surname><given-names>Ad&#x000e9;la</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Beilhack</surname><given-names>Georg</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Levkau</surname><given-names>Bodo</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Voelkl</surname><given-names>Jakob</given-names></name><address><email>jakob.voelkl@jku.at</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff5">5</xref><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Alesutan</surname><given-names>Ioana</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/052r2xn60</institution-id><institution-id institution-id-type="GRID">grid.9970.7</institution-id><institution-id institution-id-type="ISNI">0000 0001 1941 5140</institution-id><institution>Institute for Physiology and Pathophysiology, </institution><institution>Johannes Kepler University Linz, </institution></institution-wrap>Krankenhausstrasse 5, 4020 Linz, Austria </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/052r2xn60</institution-id><institution-id institution-id-type="GRID">grid.9970.7</institution-id><institution-id institution-id-type="ISNI">0000 0001 1941 5140</institution-id><institution>Institute of Biophysics, </institution><institution>Johannes Kepler University Linz, </institution></institution-wrap>Linz, Austria </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05n3x4p02</institution-id><institution-id institution-id-type="GRID">grid.22937.3d</institution-id><institution-id institution-id-type="ISNI">0000 0000 9259 8492</institution-id><institution>Division of Nephrology and Dialysis, Department of Medicine III, </institution><institution>Medical University of Vienna, </institution></institution-wrap>Vienna, Austria </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/024z2rq82</institution-id><institution-id institution-id-type="GRID">grid.411327.2</institution-id><institution-id institution-id-type="ISNI">0000 0001 2176 9917</institution-id><institution>Institute of Molecular Medicine III, </institution><institution>University Hospital and Heinrich Heine University D&#x000fc;sseldorf, </institution></institution-wrap>D&#x000fc;sseldorf, Germany </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/001w7jn25</institution-id><institution-id institution-id-type="GRID">grid.6363.0</institution-id><institution-id institution-id-type="ISNI">0000 0001 2218 4662</institution-id><institution>Department of Nephrology and Medical Intensive Care, </institution><institution>Charit&#x000e9;-Universit&#x000e4;tsmedizin Berlin, </institution></institution-wrap>Berlin, Germany </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/031t5w623</institution-id><institution-id institution-id-type="GRID">grid.452396.f</institution-id><institution-id institution-id-type="ISNI">0000 0004 5937 5237</institution-id><institution>DZHK (German Centre for Cardiovascular Research), Partner Site Berlin, </institution></institution-wrap>Berlin, Germany </aff></contrib-group><pub-date pub-type="epub"><day>3</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="pmc-release"><day>3</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="ppub"><year>2025</year></pub-date><volume>477</volume><issue>6</issue><fpage>815</fpage><lpage>826</lpage><history><date date-type="received"><day>4</day><month>6</month><year>2024</year></date><date date-type="rev-recd"><day>19</day><month>1</month><year>2025</year></date><date date-type="accepted"><day>20</day><month>1</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><p id="Par1">Medial vascular calcification is common in chronic kidney disease patients and linked to hyperphosphatemia. Upon phosphate exposure, intricate signaling events orchestrate pro-calcific effects in the vasculature mediated by vascular smooth muscle cells (VSMCs). Sphingosine kinase 1 (SPHK1) produces sphingosine-1-phosphate (S1P) and is associated with complex effects in the vascular system. The present study investigated a possible involvement of SPHK1 in VSMC calcification. Experiments were performed in primary human aortic VSMCs under pro-calcific conditions, with pharmacological inhibition or knockdown of SPHK1 or SPNS2 (a lysolipid transporter involved in cellular S1P export), as well as in Sphk1-deficient and wild-type mice treated with cholecalciferol. In VSMCs, SPHK1 expression was up-regulated by pro-calcific conditions. Calcification medium up-regulated osteogenic marker mRNA expression and activity as well as calcification of VSMCs, effects significantly augmented by co-treatment with the SPHK1 inhibitor SK1-IN-1. SK1-IN-1 alone was sufficient to up-regulate osteogenic signaling in VSMCs during control conditions. Similarly, the SPHK1 inhibitor PF-543 and SPHK1 knockdown up-regulated osteogenic signaling in VSMCs and aggravated VSMC calcification. In contrast, co-treatment with the SPNS2 inhibitor SLF1081851 suppressed osteogenic signaling and calcification of VSMCs, effects abolished by silencing of SPHK1. In addition, Sphk1 deficiency aggravated vascular calcification and aortic osteogenic marker expression in mice after cholecalciferol overload. In conclusion, SPHK1 inhibition, knockdown, or deficiency aggravates vascular pro-calcific signaling and calcification. The reduced calcification after inhibition of S1P export suggests a possible involvement of intracellular S1P, but further studies are required to elucidate the complex roles of SPHKs and S1P signaling in calcifying VSMCs.</p></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Sphingosine kinase 1</kwd><kwd>Phosphate</kwd><kwd>Vascular smooth muscle cells</kwd><kwd>Vascular calcification</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">https://doi.org/10.13039/501100002428</institution-id><institution>Austrian Science Fund</institution></institution-wrap></funding-source><award-id>10.55776/P34724</award-id><award-id>10.55776/P34724</award-id><principal-award-recipient><name><surname>Voelkl</surname><given-names>Jakob</given-names></name><name><surname>Alesutan</surname><given-names>Ioana</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution>Johannes Kepler University Linz</institution></funding-source></award-group><open-access><p>Open access funding provided by Johannes Kepler University Linz.</p></open-access></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer-Verlag GmbH Germany, part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par2">Medial vascular calcification (VC) is defined by the accumulation of calcium phosphate complexes in the medial arterial layer [<xref ref-type="bibr" rid="CR39">39</xref>]. This type of calcification is distinct from intimal calcification, which is linked to atherosclerosis [<xref ref-type="bibr" rid="CR39">39</xref>]. VC is especially associated with chronic kidney disease (CKD), as well as diabetes mellitus and aging [<xref ref-type="bibr" rid="CR39">39</xref>, <xref ref-type="bibr" rid="CR70">70</xref>]. The presence of VC is an independent risk factor for mortality [<xref ref-type="bibr" rid="CR39">39</xref>], and no broadly applicable therapeutic strategies are available.</p><p id="Par3">Complex local and systemic events act in concert to promote VC [<xref ref-type="bibr" rid="CR71">71</xref>], where an important regulatory role is attributed to vascular smooth muscle cells (VSMCs) [<xref ref-type="bibr" rid="CR18">18</xref>]. VSMCs are able to facilitate a pro-calcific micro-environment in response to various stimuli, such as inflammatory mediators [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR6">6</xref>], endothelial dysfunction, and unphysiological stress [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR66">66</xref>, <xref ref-type="bibr" rid="CR76">76</xref>]. One of the most powerful promotors of VC is disturbed phosphate homeostasis with hyperphosphatemia in CKD [<xref ref-type="bibr" rid="CR33">33</xref>]. The pro-calcific effects of VSMCs are mediated by various factors to directly or indirectly augment the formation of calcium phosphate crystals, such as extracellular vesicle release [<xref ref-type="bibr" rid="CR58">58</xref>], release of inflammatory mediators [<xref ref-type="bibr" rid="CR71">71</xref>], or degradation of the calcification inhibitor pyrophosphate by tissue-nonspecific alkaline phosphatase (ALPL) [<xref ref-type="bibr" rid="CR65">65</xref>]. The calcific response of VSMCs is linked to the activation of pro-calcific transcription factors such as core-binding factor alpha 1 (CBFA1, also known as runt-related transcription factor 2 or RUNX2), which is required for the development of VC [<xref ref-type="bibr" rid="CR41">41</xref>, <xref ref-type="bibr" rid="CR42">42</xref>]. Various inflammatory and other pathways converge on a pro-calcific gene expression profile, but the multifaceted upstream components are still incompletely defined [<xref ref-type="bibr" rid="CR70">70</xref>].</p><p id="Par4">Sphingosine-1-phosphate (S1P) is a vasoactive sphingolipid, with a complex role in vascular tone, endothelial barrier function, and lymphocyte trafficking [<xref ref-type="bibr" rid="CR34">34</xref>]. Both intra- and extra-cellular functions of S1P are described [<xref ref-type="bibr" rid="CR62">62</xref>]. In macrophages, S1P induces ATP efflux, which is the substrate for the formation of the anti-calcific pyrophosphate by ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR67">67</xref>]. S1P is formed by the phosphorylation of sphingosine through sphingosine kinases (SPHKs) SPHK1 and SPHK2 [<xref ref-type="bibr" rid="CR73">73</xref>]. S1P can be transported outside the cell through SPNS lysolipid transporter 2, S1P (SPNS2) [<xref ref-type="bibr" rid="CR30">30</xref>]. The SPHKs differ in subcellular distribution and function [<xref ref-type="bibr" rid="CR55">55</xref>]. SPHK1 is expressed in VSMCs, and its deficiency reduces proliferation and protects from pulmonary hypertension [<xref ref-type="bibr" rid="CR16">16</xref>]. SPHK1 inhibition also impacts on atherosclerosis [<xref ref-type="bibr" rid="CR55">55</xref>]. In calcifying VSMCs, S1P production is increased, where extracellular S1P promotes calcification [<xref ref-type="bibr" rid="CR46">46</xref>]. SPHK function may also govern the balance between S1P and ceramide, which have been associated with opposite effects in apoptosis signaling [<xref ref-type="bibr" rid="CR48">48</xref>]. The ceramide system has been linked to cardiovascular calcification. A pro-calcific role of acid sphingomyelinase [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR43">43</xref>], neutral sphingomyelinase 2 [<xref ref-type="bibr" rid="CR52">52</xref>], or ceramide synthase 5 [<xref ref-type="bibr" rid="CR57">57</xref>] was described, while the acid ceramidase was shown to mediate anti-calcific effects [<xref ref-type="bibr" rid="CR11">11</xref>].</p><p id="Par5">In view of the complex roles attributed to SPHKs and S1P, the present study explores the putative function of SPHK1 in VSMC calcification during exposure to elevated phosphate concentrations.</p></sec><sec id="Sec2"><title>Materials and methods</title><sec id="Sec3"><title>Cell culture</title><p id="Par6">Primary human aortic smooth muscle cells (HAoSMCs, Fisher Scientific) [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR26">26</xref>] were routinely cultured in a medium containing a 1:1 ratio of Waymouth&#x02019;s MB 752/1 and Ham&#x02019;s F-12 nutrient mix supplemented with 10% FBS, 100 U/ml penicillin, and 100&#x000a0;&#x000b5;g/ml streptomycin (all from Fisher Scientific) and were used in experiments up to passage 12. Cells were treated for the indicated times with calcification medium (culture medium additionally supplemented with 10&#x000a0;mM &#x003b2;-glycerophosphate and 1.5&#x000a0;mM CaCl<sub>2</sub> (Sigma Aldrich)) and/or with 10&#x000a0;&#x000b5;M SK1-IN-1 (SPHK1 inhibitor, stock in DMSO, MedChemExpress) [<xref ref-type="bibr" rid="CR74">74</xref>], 10&#x000a0;&#x000b5;M PF-543 (SPHK1 inhibitor, stock in DMSO, MedChemExpress) [<xref ref-type="bibr" rid="CR23">23</xref>], and 3&#x000a0;&#x000b5;M SLF1081851 (SPNS2 inhibitor, stock in ethanol, MedChemExpress) [<xref ref-type="bibr" rid="CR22">22</xref>]. Treatment with equal amounts of vehicle were used as control. Where indicated, cells were transfected with 10&#x000a0;nM SPHK1 (ID: s16959) or negative control (ID: 4390843) siRNA using siPORT amine transfection reagent (all from Fisher Scientific). For long-term treatments, fresh medium with agents were added every 2&#x02013;3&#x000a0;days.</p></sec><sec id="Sec4"><title>Animal experiments</title><p id="Par7">All animal experiments were approved by the local authorities (BMBWF Vienna, Austria, 66.009/0320-V/3b/2019). The generation and origin of Sphk1-deficient mice was described previously [<xref ref-type="bibr" rid="CR8">8</xref>]. Calcification was induced by high-dosed cholecalciferol treatment [<xref ref-type="bibr" rid="CR3">3</xref>] in male Sphk1-deficient (sphk1<sup>&#x02212;/&#x02212;</sup>) and corresponding wild-type (sphk1<sup>+/+</sup>) mice. Mice were injected subcutaneously with 500,000&#x000a0;IU/kg BW of cholecalciferol (Sigma Aldrich) or vehicle for 3 successive days. On day 6, blood was collected by retroorbital puncture and mice were sacrificed by cervical dislocation during isoflurane anesthesia. Aortic arches (calcium content) and thoracic aorta (mRNA expression) were snap frozen for further experiments (<italic>n</italic>&#x02009;=&#x02009;5). Serum concentrations of calcium and phosphate were determined by using a photometric method (FUJI Dri-Chem Nx700). For Alizarin Red staining (<italic>n</italic>&#x02009;=&#x02009;4), whole aortas were carefully excised and stained with Alizarin Red (0.0016% in 0.5% KOH) [<xref ref-type="bibr" rid="CR7">7</xref>].</p></sec><sec id="Sec5"><title>RNA isolation and RT-PCR</title><p id="Par8">Total RNA was isolated by using Trizol Reagent (Fisher Scientific), and reverse transcription was performed by using SuperScript III Reverse Transcriptase and oligo(dT)<sub>12&#x02013;18</sub> primers (Fisher Scientific). RT-PCR was performed in duplicate with iQ Sybr Green Supermix (Bio-Rad Laboratories) and the following primers (Fisher Scientific) [<xref ref-type="bibr" rid="CR69">69</xref>, <xref ref-type="bibr" rid="CR72">72</xref>]:</p><p id="Par9">Human primers:<list list-type="bullet"><list-item><p id="Par10"><italic>ALPL</italic> fw: GGGACTGGTACTCAGACAACG</p></list-item><list-item><p id="Par11"><italic>ALPL</italic> rev: GTAGGCGATGTCCTTACAGCC</p></list-item><list-item><p id="Par12"><italic>CBFA1</italic> fw: GCCTTCCACTCTCAGTAAGAAGA</p></list-item><list-item><p id="Par13"><italic>CBFA1</italic> rev: GCCTGGGGTCTGAAAAAGGG</p></list-item><list-item><p id="Par14"><italic>GAPDH</italic> fw: GAGTCAACGGATTTGGTCGT</p></list-item><list-item><p id="Par15"><italic>GAPDH</italic> rev: GACAAGCTTCCCGTTCTCAG</p></list-item><list-item><p id="Par16"><italic>SPHK1</italic> fw: GGCTGCTGTCACCCATGAA</p></list-item></list><list list-type="bullet"><list-item><p id="Par17"><italic>SPHK1</italic> rev: TCACTCTCTAGGTCCACATCAG</p></list-item></list></p><p id="Par18">Mouse primers:<list list-type="bullet"><list-item><p id="Par19"><italic>Alpl</italic> fw: TTGTGCCAGAGAAAGAGAGAGA</p></list-item><list-item><p id="Par20"><italic>Alpl</italic> rev: GTTTCAGGGCATTTTTCAAGGT</p></list-item><list-item><p id="Par21"><italic>Cbfa1</italic> fw: AGAGTCAGATTACAGATCCCAGG</p></list-item><list-item><p id="Par22"><italic>Cbfa1</italic> rev: AGGAGGGGTAAGACTGGTCATA</p></list-item><list-item><p id="Par23"><italic>Gapdh</italic> fw: AGGTCGGTGTGAACGGATTTG</p></list-item></list><list list-type="bullet"><list-item><p id="Par24"><italic>Gapdh</italic> rev: TGTAGACCATGTAGTTGAGGTCA</p></list-item></list></p><p id="Par25">Relative mRNA fold changes were calculated by the 2<sup>&#x02212;&#x00394;&#x00394;Ct</sup> method using GAPDH as internal reference.</p></sec><sec id="Sec6"><title>Protein isolation and Western blotting</title><p id="Par26">Total proteins were isolated by using ice-cold Pierce IP lysis buffer supplemented with complete protease and phosphatase inhibitors cocktail (all from Fisher Scientific), and protein concentration was determined by the Bradford assay (Bio-Rad Laboratories). Equal amounts of protein were boiled in Roti-Load1 Buffer (Carl Roth) at 100&#x000a0;&#x000b0;C for 10&#x000a0;min and then separated on SDS-PAGE gels and transferred to PVDF membranes (Roche Applied Science). Membranes were incubated with primary antibodies: rabbit anti-SPHK1 (1:1000, #12071, Cell Signaling) and rabbit anti-GAPDH (1:3000, #2118, Cell Signaling) at 4&#x000a0;&#x000b0;C overnight and with secondary anti-rabbit HRP-conjugated antibody (1:1000, Cell Signaling) at room temperature for 1&#x000a0;h. Membranes were stripped with Restore Plus Western blot stripping buffer (Fisher Scientific) at room temperature. Bands were detected with Clarity Western ECL substrate (Bio-Rad Laboratories) using the ChemiDoc MP imaging system (Bio-Rad Laboratories) and quantified using the ImageJ software. Data are shown as the ratio of total protein to GAPDH, normalized to the control group [<xref ref-type="bibr" rid="CR28">28</xref>].</p></sec><sec id="Sec7"><title>Immunofluorescence staining</title><p id="Par27">HAoSMCs were fixed in 4% PFA/PBS for 15&#x000a0;min at room temperature, permeabilized in 0.3% TritonX-100/PBS for 10&#x000a0;min at room temperature, and blocked with 5% goat serum in 0.1% TritonX-100/PBS for 60&#x000a0;min at room temperature. Cells were incubated with primary rabbit anti-RUNX2 antibody (1:100 in 0.1% TritonX-100/PBS, #12556, Cell Signaling) [<xref ref-type="bibr" rid="CR7">7</xref>] overnight at 4&#x000a0;&#x000b0;C and then with goat anti-rabbit Alexa488-conjugated antibody (1:500 in 0.1% TritonX-100/PBS, Invitrogen) for 2&#x000a0;h at room temperature. Nuclei were stained with 0.5&#x000a0;&#x000b5;g/ml DAPI (Carl Roth) for 5&#x000a0;min at room temperature, and slides were mounted with Prolong Diamond antifade reagent (Invitrogen). Images were acquired on a Nikon Ti-2 microscope (&#x000d7;&#x02009;60 oil immersion, NA 1.42) equipped with a Clarity Laser Free Confocal Unit (Aurox).</p></sec><sec id="Sec8"><title>ALP activity</title><p id="Par28">ALP activity in cell lysates was determined by using a colorimetric ALP assay kit (Abcam) and protein concentration was determined by the Bradford assay (Bio-Rad Laboratories). Data are shown normalized to total protein concentration and to the control group [<xref ref-type="bibr" rid="CR6">6</xref>].</p></sec><sec id="Sec9"><title>Calcification staining</title><p id="Par29">At the end of the treatment period, cells were incubated with OsteoSense 680EX (1:250, Perkin Elmer) overnight at 37&#x000a0;&#x000b0;C, and images were acquired with the ChemiDoc MP imaging system (Bio-Rad Laboratories) [<xref ref-type="bibr" rid="CR53">53</xref>].</p></sec><sec id="Sec10"><title>Quantification of calcium content</title><p id="Par30">Cells and aortic tissues were decalcified in 0.6&#x000a0;M HCl overnight at 4&#x000a0;&#x000b0;C and 37&#x000a0;&#x000b0;C, respectively. The calcium content in the supernatant was quantified by using the QuantiChrom Calcium assay kit (BioAssay Systems). Proteins were isolated by using 0.1&#x000a0;M NaOH/ 0.1% SDS buffer and quantified by the Bradford assay (Bio-Rad Laboratories). Data are shown normalized to total protein concentration and to the control group [<xref ref-type="bibr" rid="CR47">47</xref>].</p></sec><sec id="Sec11"><title>Statistics</title><p id="Par31">Data are shown as scatter dot plots and arithmetic means&#x02009;&#x000b1;&#x02009;SEM, and<italic> n</italic> represents the number of independent experiments performed. Normalized data are presented as arbitrary units (a.u.). Normality was determined by the Shapiro&#x02013;Wilk test. For multiple group comparison, statistical testing was performed by using one-way ANOVA with Tukey&#x02019;s test (homoscedastic data) or Games-Howell test (heteroscedastic data) and Kruskal&#x02013;Wallis with Steel&#x02013;Dwass test (non-normal data). For two groups, statistical testing was performed using <italic>T</italic>-test. <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05 was considered statistically significant.</p></sec></sec><sec id="Sec12"><title>Results</title><p id="Par32">To investigate whether SPHK1 may play a role in VSMC calcification during pro-calcific conditions, a first series of experiments was performed in primary HAoSMCs following exposure to control medium or calcification medium supplemented with calcium and the phosphate donor &#x003b2;-glycerophosphate. As a result, <italic>SPHK1</italic> mRNA expression (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>a) and protein abundance (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>b) were significantly higher in HAoSMCs treated for 24&#x000a0;h with calcification medium as compared to control HAoSMCs.<fig id="Fig1"><label>Fig.&#x000a0;1</label><caption><p>SPHK1 expression was up-regulated in VSMCs during pro-calcific conditions. <bold>a</bold> Relative mRNA expression (<italic>n</italic>&#x02009;=&#x02009;4) of <italic>SPHK1</italic> in HAoSMCs treated for 24&#x000a0;h with control (CTR) or calcification medium (Calc.). <bold>b</bold> Representative Western blots and normalized SPHK1 protein abundance (<italic>n</italic>&#x02009;=&#x02009;8) in HAoSMCs treated for 24&#x000a0;h with control (CTR) or calcification medium (Calc.). *(<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05), **(<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01) significant vs. control group</p></caption><graphic xlink:href="424_2025_3068_Fig1_HTML" id="MO1"/></fig></p><p id="Par33">Next, the effects of SPHK1 suppression using pharmacological inhibitors on calcification medium-induced osteogenic signaling and VSMC calcification were determined. As shown in Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>a, b, calcification medium induced&#x000a0;up-regulated mRNA expression of the&#x000a0;osteogenic markers <italic>CBFA1</italic> and <italic>ALPL</italic>, effects significantly augmented in the presence of the SPHK1 inhibitor SK1-IN-1. Treatment with SK1-IN-1 alone was sufficient to up-regulate osteogenic marker expression in HAoSMCs. As shown by immunostaining and confocal microscopy, SK1-IN-1 increased CBFA1 nuclear localization in HAoSMCs (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>c). In addition, SK1-IN-1 significantly increased ALP activity and augmented calcification medium-induced ALP activity in HAoSMCs (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>d). More importantly, as illustrated by Osteosense fluorescence imaging and quantification of calcium content, SK1-IN-1 did not significantly modify calcification of HAoSMCs during control conditions, but significantly aggravated HAoSMC calcification induced by the calcification medium (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>e, f).<fig id="Fig2"><label>Fig.&#x000a0;2</label><caption><p>The SPHK1 inhibitor SK1-IN-1 augmented osteogenic marker expression and activity as well as calcification of VSMCs during pro-calcific conditions. Relative mRNA expression (<italic>n</italic>&#x02009;=&#x02009;6) of <italic>CBFA1</italic> (<bold>a</bold>) and <italic>ALPL</italic> (<bold>b</bold>) in HAoSMCs treated for 48&#x000a0;h with control (CTR) or calcification medium (Calc.) without and with 10&#x000a0;&#x000b5;M SK1-IN-1 (SK1). <bold>c</bold> CBFA1 (green) and nuclei (blue) shown by confocal imaging in HAoSMCs treated for 48&#x000a0;h with control (CTR) or 10&#x000a0;&#x000b5;M SK1-IN-1 (SK1). Scale bar: 20&#x000a0;&#x000b5;m. <bold>d</bold> Normalized ALP activity (<italic>n</italic>&#x02009;=&#x02009;8) in HAoSMCs treated for 7&#x000a0;days with control (CTR) or calcification medium (Calc.) without and with 10&#x000a0;&#x000b5;M SK1-IN-1 (SK1). Calcification detected by Osteosense fluorescence imaging (<bold>e</bold>) and normalized calcium content (<bold>f</bold>) (<italic>n</italic>&#x02009;=&#x02009;7) in HAoSMCs treated for 11&#x000a0;days with control (CTR) or calcification medium (Calc.) without and with 10&#x000a0;&#x000b5;M SK1-IN-1 (SK1). Calcified areas: white pseudocolor. *(<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05), **(<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01), ***(<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001) significant vs. control group; &#x02020;(<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05), &#x02020;&#x02020;(<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01) significant vs. Calc.-treated group</p></caption><graphic xlink:href="424_2025_3068_Fig2_HTML" id="MO2"/></fig></p><p id="Par34">Similarly, the SPHK1 inhibitor PF-543 significantly increased the mRNA expression of <italic>CBFA1</italic> and tended to up-regulate <italic>ALPL</italic> mRNA expression, a difference, however, not reaching statistical significance (<italic>p</italic>&#x02009;=&#x02009;0.075), in HAoSMCs during control conditions (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>a, b). Furthermore, PF-543 significantly augmented calcification medium-induced osteogenic markers mRNA expression as well as calcification of HAoSMCs (Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>a&#x02013;d). Taken together, SPHK1 inhibition promoted osteogenic signaling in VSMCs and augmented osteogenic marker expression and calcification of VSMCs during pro-calcific conditions.<fig id="Fig3"><label>Fig.&#x000a0;3</label><caption><p>The SPHK1 inhibitor PF-543 augmented osteogenic marker expression and calcification of VSMCs during pro-calcific conditions. Relative mRNA expression (<italic>n</italic>&#x02009;=&#x02009;6) of <italic>CBFA1</italic> (<bold>a</bold>) and <italic>ALPL</italic> (<bold>b</bold>) in HAoSMCs treated for 48&#x000a0;h with control (CTR) or calcification medium (Calc.) without and with 10&#x000a0;&#x000b5;M PF-543 (PF). Calcification detected by Osteosense fluorescence imaging (<bold>c</bold>) and normalized calcium content (<bold>d</bold>) (<italic>n</italic>&#x02009;=&#x02009;6) in HAoSMCs treated for 11&#x000a0;days with control (CTR) or calcification medium (Calc.) without and with 10&#x000a0;&#x000b5;M PF-543 (PF). Calcified areas: white pseudocolor. *(<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05), **(<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01), ***(<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001) significant vs. control group; &#x02020;(<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05), &#x02020;&#x02020;(<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01) significant vs. Calc.-treated group</p></caption><graphic xlink:href="424_2025_3068_Fig3_HTML" id="MO3"/></fig></p><p id="Par35">In further experiments, the effects of SPNS2 transporter inhibition by using SLF1081851 to block S1P export on osteogenic signaling and VSMC calcification during pro-calcific conditions were investigated. Co-treatment with SLF1081851 significantly suppressed osteogenic marker expression induced by calcification medium in HAoSMCs (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>a, b). In addition, SLF1081851 significantly reduced the calcification of HAoSMCs during pro-calcific conditions (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>c, d). Thus, blockage of S1P export via SPNS2 was able to ameliorate osteogenic signaling and calcification of VSMCs during pro-calcific conditions.<fig id="Fig4"><label>Fig.&#x000a0;4</label><caption><p>The SPNS2 inhibitor SLF1081851 reduced osteogenic marker expression and calcification of VSMCs during pro-calcific conditions. Relative mRNA expression (<italic>n</italic>&#x02009;=&#x02009;6) of <italic>CBFA1</italic> (<bold>a</bold>) and <italic>ALPL</italic> (<bold>b</bold>) in HAoSMCs treated for 48&#x000a0;h with control (CTR) or calcification medium (Calc.) without and with 3&#x000a0;&#x000b5;M SLF1081851 (SLF). Calcification detected by Osteosense fluorescence imaging (<bold>c</bold>) and normalized calcium content (<bold>d</bold>) (<italic>n</italic>&#x02009;=&#x02009;6) in HAoSMCs treated for 11&#x000a0;days with control (CTR) or calcification medium (Calc.) without and with 3&#x000a0;&#x000b5;M SLF1081851 (SLF). Calcified areas: white pseudocolor. *(<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05), **(<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01), ***(<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001) significant vs. control group; &#x02020;(<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05), &#x02020;&#x02020;(<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01) significant vs. Calc.-treated group</p></caption><graphic xlink:href="424_2025_3068_Fig4_HTML" id="MO4"/></fig></p><p id="Par36">In the next series of experiments, the endogenous expression of SPHK1 was suppressed by using small interfering RNA (siRNA) in HAoSMCs exposed to control or calcification medium. To indicate a role of intracellular S1P during SPHK1 knockdown, experiments were conducted in the presence and absence of the SPNS2 inhibitor SLF1081851. As a result, transfection with SPHK1 siRNA significantly reduced <italic>SPHK1</italic> mRNA expression in HAoSMCs as compared to negative control siRNA-transfected HAoSMCs (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>a). In accordance with our previous finding, exposure to calcification medium significantly increased <italic>SPHK1</italic> mRNA expression, an effect not significantly modified by co-treatment with SLF1081851. Knockdown of SPHK1 significantly up-regulated <italic>CBFA1</italic> and <italic>ALPL</italic> mRNA expression as well as ALP activity in HAoSMCs (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>b&#x02013;d) and significantly augmented calcification medium-induced <italic>CBFA1</italic> mRNA expression and ALP activity and tended to increase calcification medium-induced <italic>ALPL</italic> mRNA expression (<italic>p</italic>&#x02009;=&#x02009;0.095). Furthermore, silencing of SPHK1 significantly reversed the protective effects of SLF1081851 on osteogenic marker expression and ALP activity in HAoSMCs. In accordance, silencing of SPHK1 aggravated HAoSMC calcification and abolished the anti-calcific effects of SLF1081851 during pro-calcific conditions (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref>). Taken together, knockdown of SPHK1 promoted osteogenic signaling and augmented calcification of VSMCs during pro-calcific conditions. In addition, blockage of S1P export via SPNS2 failed to reduce osteogenic signaling and calcification of SPHK1-silenced VSMCs during pro-calcific conditions.<fig id="Fig5"><label>Fig.&#x000a0;5</label><caption><p>SPHK1 knockdown augmented osteogenic marker expression and activity and suppressed the protective effects of SPNS2 inhibition during pro-calcific conditions. Relative mRNA expression (<italic>n</italic>&#x02009;=&#x02009;10) of <italic>SPHK1</italic> (<bold>a</bold>), <italic>CBFA1</italic> (<bold>b</bold>), and <italic>ALPL</italic> (<bold>c</bold>) in HAoSMCs transfected for 72&#x000a0;h with negative control siRNA (Neg.si) or SPHK1 siRNA (SPHK1si) and treated for 48&#x000a0;h with control or calcification medium (Calc.) without and with 3&#x000a0;&#x000b5;M SLF1081851 (SLF). <bold>d</bold> Normalized ALP activity (<italic>n</italic>&#x02009;=&#x02009;8) in HAoSMCs transfected with negative control siRNA (Neg.si) or SPHK1 siRNA (SPHK1si) and treated for 7&#x000a0;days with control or calcification medium (Calc.) without and with 3&#x000a0;&#x000b5;M SLF1081851 (SLF). *(<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05), **(<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01), ***(<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001) significant vs. Neg.si-transfected group; &#x02020;(<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05), &#x02020;&#x02020;&#x02020;(<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001) significant vs. Neg.si&#x02009;+&#x02009;Calc.-treated group; &#x02021;(<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05), &#x02021;&#x02021;(<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01), &#x02021;&#x02021;&#x02021;(<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001) significant between Neg.si&#x02009;+&#x02009;Calc.&#x02009;+&#x02009;SLF- and SPHK1si&#x02009;+&#x02009;Calc.&#x02009;+&#x02009;SLF-treated groups</p></caption><graphic xlink:href="424_2025_3068_Fig5_HTML" id="MO5"/></fig><fig id="Fig6"><label>Fig.&#x000a0;6</label><caption><p>SPHK1 knockdown aggravated VSMC calcification and abolished the protective effects of SPNS2 inhibition during pro-calcific conditions. Calcification detected by Osteosense fluorescence imaging (<bold>a</bold>) and normalized calcium content (<bold>b</bold>) (<italic>n</italic>&#x02009;=&#x02009;8) in HAoSMCs transfected with negative control siRNA (Neg.si) or SPHK1 siRNA (SPHK1si) and treated for 11&#x000a0;days with control (CTR) or calcification medium (Calc.) without and with 3&#x000a0;&#x000b5;M SLF1081851 (SLF). Calcified areas: white pseudocolor. *(<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05) significant vs. Neg.si-transfected group; &#x02020;(<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05) significant vs. Neg.si&#x02009;+&#x02009;Calc.-treated group; &#x02021;(p&#x02009;&#x0003c;&#x02009;0.05) significant between Neg.si&#x02009;+&#x02009;Calc.&#x02009;+&#x02009;SLF- and SPHK1si&#x02009;+&#x02009;Calc.&#x02009;+&#x02009;SLF-treated groups</p></caption><graphic xlink:href="424_2025_3068_Fig6_HTML" id="MO6"/></fig></p><p id="Par37">To confirm the in vitro findings, additional experiments were performed in vivo in the cholecalciferol overload-induced VC mouse model using the Sphk1-deficient (sphk1<sup>&#x02212;/&#x02212;</sup>) and corresponding wild-type (sphk1<sup>+/+</sup>) mice. As shown in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>, the serum calcium and phosphate levels were similar in both genotypes treated with high-dosed cholecalciferol. More importantly, as shown by Alizarin Red staining and quantification of calcium content, the aortic calcification was significantly higher in the cholecalciferol-treated sphk1<sup>&#x02212;/&#x02212;</sup> mice as compared to sphk1<sup>+/+</sup> mice (Fig.&#x000a0;<xref rid="Fig7" ref-type="fig">7</xref>a, b). In accordance, the aortic osteogenic marker <italic>Cbfa1</italic> and <italic>Alpl</italic> mRNA expression were significantly higher in the cholecalciferol-treated sphk1<sup>&#x02212;/&#x02212;</sup> mice as compared to sphk1<sup>+/+</sup> mice (Fig.&#x000a0;<xref rid="Fig7" ref-type="fig">7</xref>c, d). Thus, Sphk1 deficiency aggravated VC in mice during cholecalciferol overload.
<table-wrap id="Tab1"><label>Table&#x000a0;1</label><caption><p>Effects of Sphk1 deficiency in mice during cholecalciferol overload. Serum calcium and phosphate levels in Sphk1-deficient (sphk1<sup>&#x02212;/&#x02212;</sup>) and corresponding wild-type (sphk1<sup>+/+</sup>) mice receiving high-dosed cholecalciferol (vD)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left"/><th align="left">sphk1<sup>+/+</sup><break/>vD</th><th align="left">sphk1<sup>&#x02212;/&#x02212;</sup><break/>vD</th><th align="left"><italic>p</italic>-value</th><th align="left"/></tr></thead><tbody><tr><td align="left">Calcium [mg/dl]</td><td char="." align="char">19.56&#x02009;&#x000b1;&#x02009;1.02</td><td char="&#x000b1;" align="char">21.00&#x02009;&#x000b1;&#x02009;0.78</td><td char="." align="char">0.295</td><td char="." align="char"><italic>n</italic>&#x02009;=&#x02009;5</td></tr><tr><td align="left">Phosphate [mg/dl]</td><td char="." align="char">8.14&#x02009;&#x000b1;&#x02009;0.17</td><td char="&#x000b1;" align="char">7.92&#x02009;&#x000b1;&#x02009;0.57</td><td char="." align="char">0.719</td><td char="." align="char"><italic>n</italic>&#x02009;=&#x02009;5</td></tr></tbody></table></table-wrap><fig id="Fig7"><label>Fig.&#x000a0;7</label><caption><p>Sphk1 deficiency aggravated vascular calcification in mice during cholecalciferol overload. <bold>a</bold> Alizarin Red staining of aortas from Sphk1-deficient (sphk1<sup>&#x02212;/&#x02212;</sup>) and corresponding wild-type (sphk1<sup>+/+</sup>) mice receiving high-dosed cholecalciferol (vD). Calcification: red staining; scale bar: 5&#x000a0;mm. Normalized calcium content (<bold>b</bold>) as well as relative mRNA expression of <italic>Cbfa1</italic> (<bold>c</bold>) and <italic>Alpl</italic> (<bold>d</bold>) (<italic>n</italic>&#x02009;=&#x02009;5) in aortic tissue from Sphk1-deficient (sphk1<sup>&#x02212;/&#x02212;</sup>) and corresponding wild-type (sphk1<sup>+/+</sup>) mice receiving high-dosed cholecalciferol (vD). *(<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05), **(<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.01) significant vs sphk1<sup>+/+</sup> vD-treated group</p></caption><graphic xlink:href="424_2025_3068_Fig7_HTML" id="MO7"/></fig></p></sec><sec id="Sec13"><title>Discussion</title><p id="Par38">The present study discloses a novel role of SPHK1 in the signaling of VSMC calcification in vitro and in vivo. Pharmacological inhibition, knockdown, or deficiency of SPHK1 augments VSMC calcification. Moreover, inhibition of S1P export via SPNS2 is protective during VSMC calcification in vitro.</p><p id="Par39">These findings add a further aspect to the complex role of SPHKs in cardiovascular pathologies. Up-regulation of SPHK1 is observed in VSMCs during calcifying conditions, as was also reported previously in bovine VSMCs [<xref ref-type="bibr" rid="CR46">46</xref>]. Platelet-derived growth factor (PDGF), a potent stimulator of VSMC calcification [<xref ref-type="bibr" rid="CR68">68</xref>], increases SPHK1 expression in VSMCs [<xref ref-type="bibr" rid="CR21">21</xref>]. Increased SPHK1 expression is also observed in calcified aortic valves [<xref ref-type="bibr" rid="CR9">9</xref>]. In theory, up-regulation of SPHK1 could be a general response to stressed conditions and pro-apoptotic signaling [<xref ref-type="bibr" rid="CR24">24</xref>], which could also link to pro-calcific signaling [<xref ref-type="bibr" rid="CR17">17</xref>]. But the current findings are in some contrast to known functions of SPHK1 in cardiovascular pathologies and its attributed pro-inflammatory function [<xref ref-type="bibr" rid="CR14">14</xref>]. Some discrepant findings were observed in atherosclerosis development where SPHK2 inhibition by ABC294640 induces complex alterations and ultimately does not affect atherosclerosis [<xref ref-type="bibr" rid="CR54">54</xref>]. Nonetheless, aggravated atherosclerosis is observed in Sphk2- and not Sphk1-deficient mice [<xref ref-type="bibr" rid="CR32">32</xref>]. Sphk1 overexpression in Sphk2-deficient mice rescues aggravated atherosclerosis [<xref ref-type="bibr" rid="CR32">32</xref>]. Sphk1 inhibition with SKI-II exacerbates atherosclerosis in mice [<xref ref-type="bibr" rid="CR55">55</xref>]. Increasing S1P levels reduces atherosclerosis development, but its effect may depend on the S1P receptor involved and other factors [<xref ref-type="bibr" rid="CR20">20</xref>]. In contrast, pharmacological inhibition of S1P degradation by S1P lyase aggravates atherosclerosis [<xref ref-type="bibr" rid="CR37">37</xref>]. Adding further complexity, hypoxia-induced pulmonary hypertension is ameliorated by SPHK1 deficiency [<xref ref-type="bibr" rid="CR16">16</xref>]. However, silencing of SPHK1 in pulmonary VSMCs reduces the proliferative effect of PDGF [<xref ref-type="bibr" rid="CR40">40</xref>]. Despite aggravated endothelial dysfunction, the pro-calcific mediator angiotensin II [<xref ref-type="bibr" rid="CR71">71</xref>] has a reduced hypertensive effect in Sphk1-deficient mice [<xref ref-type="bibr" rid="CR61">61</xref>]. S1P maintains endothelial barrier function and induces vascular nitric oxide generation [<xref ref-type="bibr" rid="CR36">36</xref>], which has important anti-calcific effects on VSMCs [<xref ref-type="bibr" rid="CR3">3</xref>]. The expression of SPHK1 also differs among different sections of the arterial tree [<xref ref-type="bibr" rid="CR59">59</xref>]. The function of SPHK1 in the vasculature appears therefore rather complex and context-dependent.</p><p id="Par40">The diverse functional consequences of SPHK1 activation could theoretically involve differing effects of intracellular and extracellular S1P. Extracellular S1P acts through G protein-coupled receptors in the plasma membrane [<xref ref-type="bibr" rid="CR38">38</xref>]. Extracellular S1P has been shown to aggravate calcification of valvular interstitial cells through S1P receptor 2 [<xref ref-type="bibr" rid="CR9">9</xref>]. In bovine VSMCs, the addition of exogenous S1P aggravates calcification [<xref ref-type="bibr" rid="CR46">46</xref>]. Seemingly in contrast, we observe increased VSMC calcification upon SPHK1 inhibition. However, VSMC calcification appears to be reduced by inhibition of SPNS2-mediated S1P export, which is ineffective during conditions of SPHK1 knockdown. This indicates that anti-calcific effects of S1P may be mediated by its intracellular second messenger function and independent of the cell surface receptors. The importance of cellular S1P export is supported by the observation that blockade of SPNS2-mediated S1P export ameliorates renal fibrosis [<xref ref-type="bibr" rid="CR64">64</xref>]. In HK2 cells, SPHK1 silencing and SPNS2 overexpression augments the expression of connective tissue growth factor (CTGF), while SPNS2 silencing reduces it [<xref ref-type="bibr" rid="CR12">12</xref>]. CTGF itself has been linked to pro-calcific effects [<xref ref-type="bibr" rid="CR31">31</xref>]. Also, deficiency of a cardiac S1P transporter induces protection against angiotensin-II-induced cardiac remodelling, an effect attributed to elevated intracellular S1P [<xref ref-type="bibr" rid="CR19">19</xref>]. The importance of intracellular S1P in VSMCs is also indicated by the observation that intracellular S1P appears to be required for the anti-apoptotic effects of SPHK1 during high glucose conditions [<xref ref-type="bibr" rid="CR77">77</xref>]. Similarly, SPHK1 governs the induction of VSMC mitogenesis by factor-Xa [<xref ref-type="bibr" rid="CR13">13</xref>], which is able to induce VSMC senescence in atherosclerotic plaques [<xref ref-type="bibr" rid="CR60">60</xref>]. Activation of apoptotic and senescence pathways are considered hallmarks of pro-calcific signaling in VSMCs [<xref ref-type="bibr" rid="CR56">56</xref>]. Thus, deranged intracellular S1P levels could be responsible for the aggravated calcification during SPHK1 inhibition.</p><p id="Par41">However, the pathways of intracellular second messenger functions of S1P produced by SPHKs are less well defined [<xref ref-type="bibr" rid="CR62">62</xref>]. S1P regulates lysosomal function, homeostasis, and lysosome-associated membrane proteins [<xref ref-type="bibr" rid="CR75">75</xref>]. Intracellular accumulation of S1P impairs lysosomal function [<xref ref-type="bibr" rid="CR35">35</xref>], which is essential for phosphate-induced VSMC calcification [<xref ref-type="bibr" rid="CR2">2</xref>]. Other possible intracellular targets of S1P include histone deacetylases [<xref ref-type="bibr" rid="CR25">25</xref>], TNF receptor-associated factor 2 (TRAF2) [<xref ref-type="bibr" rid="CR50">50</xref>], baculoviral IAP repeat-containing protein3 (cIAP2) [<xref ref-type="bibr" rid="CR27">27</xref>], mitochondrial prohibitin 2 [<xref ref-type="bibr" rid="CR63">63</xref>], peroxisome proliferator-activated receptor (PPAR) &#x003b3; [<xref ref-type="bibr" rid="CR49">49</xref>], or heat shock proteins: heat shock protein 90 alpha family class A member 1 (HSP90&#x003b1;) and glucose-regulated protein 94 (GRP94) [<xref ref-type="bibr" rid="CR51">51</xref>].</p><p id="Par42">With the complex and incompletely defined intracellular signaling effects of S1P, the exact mechanisms underlying the pro-calcific effects of SPHK1 inhibition in VSMCs, contrasting other models [<xref ref-type="bibr" rid="CR9">9</xref>], can currently not be clearly delineated. Compared to other cell types, it could be hypothesized that VSMCs are more sensitive to intracellular S1P concentrations and the finely tuned balance of signaling molecules within this pathway. Nonetheless, other mechanisms may be of relevance for the effects of SPHK1 inhibition on VC. The effects on calcification might not be directly mediated by SPHK1, as SPHK1 and SPHK2 have diverse and sometimes opposing functions [<xref ref-type="bibr" rid="CR62">62</xref>]. But some compensatory substitution between SPHK1 and SPHK2 seems apparent. Both Sphk1- or Sphk2-deficient mice are viable, and only their double knockout leads to embryonic lethality [<xref ref-type="bibr" rid="CR45">45</xref>]. A hypothetical compensatory shift to increased SPHK2 activity during SPHK1 inhibition or deficiency could play a role in the current observation. Furthermore, the effect of SPHK1 on calcification may not be solely mediated by S1P, as SPHK1 decreases ceramide levels, while SPHK2 may increase these [<xref ref-type="bibr" rid="CR44">44</xref>]. Increased ceramide accumulation in VSMC during SPHK1 inhibition could induce pro-calcific effects [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR43">43</xref>]. Also, elevated intracellular S1P could lead to its increased intracellular degradation, where sphingosine phosphate lyase ultimately yields ethanolamine phosphate and hexadecenal [<xref ref-type="bibr" rid="CR1">1</xref>]. These degradation products themselves could exert important biological effects [<xref ref-type="bibr" rid="CR1">1</xref>]. The current study is thereby limited, as it did not determine the concentrations of S1P and its degradation products. Also, it must be kept in mind that the effects due to modifying the finely tuned balance of S1P signaling systems could be sensitive to the experimental models used and the timepoints investigated. The cell culture experiments might not completely reflect pathological processes in the human CKD patient. Also, cholecalciferol treatment induces rapid calcification in mice but differs to the calcifying conditions typically observed in CKD patients [<xref ref-type="bibr" rid="CR29">29</xref>]. Therefore, the animal experiments might be biased by the model used and sex-dependent or CKD-specific effects cannot be interpreted. Thus, the interpretations from the current observations are limited and cannot be generalized, especially towards the human patient.</p><p id="Par43">In conclusion, SPHK1 inhibitors or SPHK1 knockdown aggravate, while inhibition of S1P export ameliorates calcification in VSMCs (Fig.&#x000a0;<xref rid="Fig8" ref-type="fig">8</xref>). Sphk1 deficiency increases VC in mice after cholecalciferol treatment. These observations hint at an important function of intracellular S1P generated by SPHK1 during VC (Fig.&#x000a0;<xref rid="Fig8" ref-type="fig">8</xref>), but further studies are required to pinpoint the underlying mechanisms and the translational relevance.<fig id="Fig8"><label>Fig.&#x000a0;8</label><caption><p>Hypothesis on the impact of SPHK1 inhibition on VSMC calcification. Chronic kidney disease induces hyperphosphatemia, which trippers complex pro-calcific signaling pathways in vascular smooth muscle cells (VSMCs), fostering a pro-calcific micro-environment. Phosphate also up-regulates sphingosine kinase 1 (SPHK1) expression in VSMCs. Cellular SPHK1 mediates the synthesis of sphingosine-1-phosphate (S1P) by phosphorylation of sphingosine (Sph). Cytoplasmic S1P can be exported by sphingolipid transporter 2 (SPNS2). Extracellular S1P can induce pro-calcific effects [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR46">46</xref>], while intracellular S1P mediates anti-calcific effects by unknown mechanisms. In calcifying VSMCs, the anti-calcific effects of intracellular S1P might outweigh the pro-calcific effects of extracellular S1P, as (a) pharmacological inhibition (SK1-IN-1, PF-543), knockdown, or deficiency of SPHK1 increase pro-calcific signaling, (b) blockade of S1P export by pharmacological SPNS2 inhibition (SLF1081851) ameliorates pro-calcific signaling, and (c) the anti-calcific effects of SPNS2 inhibition are blocked during SPHK1 knockdown. However, further evidence is required to support this hypothesis and other factors or mechanisms not depicted may be involved</p></caption><graphic xlink:href="424_2025_3068_Fig8_HTML" id="MO8"/></fig></p></sec></body><back><fn-group><fn><p><bold>Publisher's Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>The authors gratefully acknowledge the technical assistance of B. Toegel.</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>J.V. and I.A. designed research; M.R., S.B., I.J., A.T., and I.A. performed experiments; M.R., S.B., G.B., B.L., J.V., and I.A. analyzed and interpreted data; J.V. and I.A. wrote the manuscript with comments and edits from all authors.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>Open access funding provided by Johannes Kepler University Linz. This work was funded by the Austrian Science Fund (FWF) (10.55776/P34724).&#x000a0;Open access funding was provided by the Austrian Science Fund.</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>No datasets were generated or analysed during the current study.</p></notes><notes><title>Declarations</title><notes id="FPar1" notes-type="COI-statement"><title>Competing interests</title><p id="Par44">The authors declare no competing interests.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name><surname>Aguilar</surname><given-names>A</given-names></name><name><surname>Saba</surname><given-names>JD</given-names></name></person-group><article-title>Truth and consequences of sphingosine-1-phosphate lyase</article-title><source>Adv Biol Regul</source><year>2012</year><volume>52</volume><issue>1</issue><fpage>17</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1016/j.advenzreg.2011.09.015</pub-id><pub-id pub-id-type="pmid">21946005</pub-id>
</element-citation><mixed-citation id="mc-CR1" publication-type="journal">Aguilar A, Saba JD (2012) Truth and consequences of sphingosine-1-phosphate lyase. Adv Biol Regul 52(1):17&#x02013;30<pub-id pub-id-type="pmid">21946005</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name><surname>Alesutan</surname><given-names>I</given-names></name><name><surname>Musculus</surname><given-names>K</given-names></name><name><surname>Castor</surname><given-names>T</given-names></name><name><surname>Alzoubi</surname><given-names>K</given-names></name><name><surname>Voelkl</surname><given-names>J</given-names></name><name><surname>Lang</surname><given-names>F</given-names></name></person-group><article-title>Inhibition of phosphate-induced vascular smooth muscle cell osteo-/chondrogenic signaling and calcification by bafilomycin A1 and methylamine</article-title><source>Kidney Blood Press Res</source><year>2015</year><volume>40</volume><issue>5</issue><fpage>490</fpage><lpage>499</lpage><pub-id pub-id-type="doi">10.1159/000368524</pub-id><pub-id pub-id-type="pmid">26418500</pub-id>
</element-citation><mixed-citation id="mc-CR2" publication-type="journal">Alesutan I, Musculus K, Castor T, Alzoubi K, Voelkl J, Lang F (2015) Inhibition of phosphate-induced vascular smooth muscle cell osteo-/chondrogenic signaling and calcification by bafilomycin A1 and methylamine. Kidney Blood Press Res 40(5):490&#x02013;499<pub-id pub-id-type="pmid">26418500</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name><surname>Alesutan</surname><given-names>I</given-names></name><name><surname>Feger</surname><given-names>M</given-names></name><name><surname>Tuffaha</surname><given-names>R</given-names></name><name><surname>Castor</surname><given-names>T</given-names></name><name><surname>Musculus</surname><given-names>K</given-names></name><name><surname>Buehling</surname><given-names>SS</given-names></name><etal/></person-group><article-title>Augmentation of phosphate-induced osteo-/chondrogenic transformation of vascular smooth muscle cells by homoarginine</article-title><source>Cardiovasc Res</source><year>2016</year><volume>110</volume><issue>3</issue><fpage>408</fpage><lpage>418</lpage><pub-id pub-id-type="doi">10.1093/cvr/cvw062</pub-id><pub-id pub-id-type="pmid">27001421</pub-id>
</element-citation><mixed-citation id="mc-CR3" publication-type="journal">Alesutan I, Feger M, Tuffaha R, Castor T, Musculus K, Buehling SS et al (2016) Augmentation of phosphate-induced osteo-/chondrogenic transformation of vascular smooth muscle cells by homoarginine. Cardiovasc Res 110(3):408&#x02013;418<pub-id pub-id-type="pmid">27001421</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name><surname>Alesutan</surname><given-names>I</given-names></name><name><surname>Voelkl</surname><given-names>J</given-names></name><name><surname>Feger</surname><given-names>M</given-names></name><name><surname>Kratschmar</surname><given-names>DV</given-names></name><name><surname>Castor</surname><given-names>T</given-names></name><name><surname>Mia</surname><given-names>S</given-names></name><etal/></person-group><article-title>Involvement of vascular aldosterone synthase in phosphate-induced osteogenic transformation of vascular smooth muscle cells</article-title><source>Sci Rep</source><year>2017</year><volume>7</volume><issue>1</issue><fpage>2059</fpage><pub-id pub-id-type="doi">10.1038/s41598-017-01882-2</pub-id><pub-id pub-id-type="pmid">28515448</pub-id>
</element-citation><mixed-citation id="mc-CR4" publication-type="journal">Alesutan I, Voelkl J, Feger M, Kratschmar DV, Castor T, Mia S et al (2017) Involvement of vascular aldosterone synthase in phosphate-induced osteogenic transformation of vascular smooth muscle cells. Sci Rep 7(1):2059<pub-id pub-id-type="pmid">28515448</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name><surname>Alesutan</surname><given-names>I</given-names></name><name><surname>Luong</surname><given-names>TTD</given-names></name><name><surname>Schelski</surname><given-names>N</given-names></name><name><surname>Masyout</surname><given-names>J</given-names></name><name><surname>Hille</surname><given-names>S</given-names></name><name><surname>Schneider</surname><given-names>MP</given-names></name><etal/></person-group><article-title>Circulating uromodulin inhibits vascular calcification by interfering with pro-inflammatory cytokine signalling</article-title><source>Cardiovasc Res</source><year>2021</year><volume>117</volume><issue>3</issue><fpage>930</fpage><lpage>941</lpage><pub-id pub-id-type="doi">10.1093/cvr/cvaa081</pub-id><pub-id pub-id-type="pmid">32243494</pub-id>
</element-citation><mixed-citation id="mc-CR5" publication-type="journal">Alesutan I, Luong TTD, Schelski N, Masyout J, Hille S, Schneider MP et al (2021) Circulating uromodulin inhibits vascular calcification by interfering with pro-inflammatory cytokine signalling. Cardiovasc Res 117(3):930&#x02013;941<pub-id pub-id-type="pmid">32243494</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name><surname>Alesutan</surname><given-names>I</given-names></name><name><surname>Henze</surname><given-names>LA</given-names></name><name><surname>Boehme</surname><given-names>B</given-names></name><name><surname>Luong</surname><given-names>TTD</given-names></name><name><surname>Zickler</surname><given-names>D</given-names></name><name><surname>Pieske</surname><given-names>B</given-names></name><etal/></person-group><article-title>Periostin augments vascular smooth muscle cell calcification via beta-catenin signaling</article-title><source>Biomolecules</source><year>2022</year><volume>12</volume><issue>8</issue><fpage>1157</fpage><pub-id pub-id-type="doi">10.3390/biom12081157</pub-id><pub-id pub-id-type="pmid">36009051</pub-id>
</element-citation><mixed-citation id="mc-CR6" publication-type="journal">Alesutan I, Henze LA, Boehme B, Luong TTD, Zickler D, Pieske B et al (2022) Periostin augments vascular smooth muscle cell calcification via beta-catenin signaling. Biomolecules 12(8):1157<pub-id pub-id-type="pmid">36009051</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name><surname>Alesutan</surname><given-names>I</given-names></name><name><surname>Razazian</surname><given-names>M</given-names></name><name><surname>Luong</surname><given-names>TTD</given-names></name><name><surname>Estepa</surname><given-names>M</given-names></name><name><surname>Pitigala</surname><given-names>L</given-names></name><name><surname>Henze</surname><given-names>LA</given-names></name><etal/></person-group><article-title>Augmentative effects of leukemia inhibitory factor reveal a critical role for TYK2 signaling in vascular calcification</article-title><source>Kidney Int</source><year>2024</year><volume>106</volume><issue>4</issue><fpage>611</fpage><lpage>624</lpage><pub-id pub-id-type="doi">10.1016/j.kint.2024.07.011</pub-id><pub-id pub-id-type="pmid">39084258</pub-id>
</element-citation><mixed-citation id="mc-CR7" publication-type="journal">Alesutan I, Razazian M, Luong TTD, Estepa M, Pitigala L, Henze LA et al (2024) Augmentative effects of leukemia inhibitory factor reveal a critical role for TYK2 signaling in vascular calcification. Kidney Int 106(4):611&#x02013;624<pub-id pub-id-type="pmid">39084258</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name><surname>Allende</surname><given-names>ML</given-names></name><name><surname>Sasaki</surname><given-names>T</given-names></name><name><surname>Kawai</surname><given-names>H</given-names></name><name><surname>Olivera</surname><given-names>A</given-names></name><name><surname>Mi</surname><given-names>Y</given-names></name><name><surname>van Echten-Deckert</surname><given-names>G</given-names></name><etal/></person-group><article-title>Mice deficient in sphingosine kinase 1 are rendered lymphopenic by FTY720</article-title><source>J Biol Chem</source><year>2004</year><volume>279</volume><issue>50</issue><fpage>52487</fpage><lpage>52492</lpage><pub-id pub-id-type="doi">10.1074/jbc.M406512200</pub-id><pub-id pub-id-type="pmid">15459201</pub-id>
</element-citation><mixed-citation id="mc-CR8" publication-type="journal">Allende ML, Sasaki T, Kawai H, Olivera A, Mi Y, van Echten-Deckert G et al (2004) Mice deficient in sphingosine kinase 1 are rendered lymphopenic by FTY720. J Biol Chem 279(50):52487&#x02013;52492<pub-id pub-id-type="pmid">15459201</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><mixed-citation publication-type="other">Benkhoff M, Barcik M, Mourikis P, Dahlmanns J, Kahmann P, Wollnitzke P, et al (2024) Targeting sphingosine-1-phosphate signaling to prevent the progression of aortic valve disease. Circulation</mixed-citation></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name><surname>Bhat</surname><given-names>OM</given-names></name><name><surname>Yuan</surname><given-names>X</given-names></name><name><surname>Cain</surname><given-names>C</given-names></name><name><surname>Salloum</surname><given-names>FN</given-names></name><name><surname>Li</surname><given-names>PL</given-names></name></person-group><article-title>Medial calcification in the arterial wall of smooth muscle cell-specific Smpd1 transgenic mice: a ceramide-mediated vasculopathy</article-title><source>J Cell Mol Med</source><year>2020</year><volume>24</volume><issue>1</issue><fpage>539</fpage><lpage>553</lpage><pub-id pub-id-type="doi">10.1111/jcmm.14761</pub-id><pub-id pub-id-type="pmid">31743567</pub-id>
</element-citation><mixed-citation id="mc-CR10" publication-type="journal">Bhat OM, Yuan X, Cain C, Salloum FN, Li PL (2020) Medial calcification in the arterial wall of smooth muscle cell-specific Smpd1 transgenic mice: a ceramide-mediated vasculopathy. J Cell Mol Med 24(1):539&#x02013;553<pub-id pub-id-type="pmid">31743567</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name><surname>Bhat</surname><given-names>OM</given-names></name><name><surname>Li</surname><given-names>G</given-names></name><name><surname>Yuan</surname><given-names>X</given-names></name><name><surname>Huang</surname><given-names>D</given-names></name><name><surname>Gulbins</surname><given-names>E</given-names></name><name><surname>Kukreja</surname><given-names>RC</given-names></name><etal/></person-group><article-title>Arterial medial calcification through enhanced small extracellular vesicle release in smooth muscle-specific Asah1 gene knockout mice</article-title><source>Sci Rep</source><year>2020</year><volume>10</volume><issue>1</issue><fpage>1645</fpage><pub-id pub-id-type="doi">10.1038/s41598-020-58568-5</pub-id><pub-id pub-id-type="pmid">32015399</pub-id>
</element-citation><mixed-citation id="mc-CR11" publication-type="journal">Bhat OM, Li G, Yuan X, Huang D, Gulbins E, Kukreja RC et al (2020) Arterial medial calcification through enhanced small extracellular vesicle release in smooth muscle-specific Asah1 gene knockout mice. Sci Rep 10(1):1645<pub-id pub-id-type="pmid">32015399</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><mixed-citation publication-type="other">Blanchard O, Stepanovska B, Starck M, Erhardt M, Romer I, Meyer Zu Heringdorf D, et al (2018) Downregulation of the S1P transporter spinster homology protein 2 (Spns2) exerts an anti-fibrotic and anti-inflammatory effect in human renal proximal tubular epithelial cells. Int J Mol Sci 19(5):1498</mixed-citation></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name><surname>Bohm</surname><given-names>A</given-names></name><name><surname>Flosser</surname><given-names>A</given-names></name><name><surname>Ermler</surname><given-names>S</given-names></name><name><surname>Fender</surname><given-names>AC</given-names></name><name><surname>Luth</surname><given-names>A</given-names></name><name><surname>Kleuser</surname><given-names>B</given-names></name><etal/></person-group><article-title>Factor-Xa-induced mitogenesis and migration require sphingosine kinase activity and S1P formation in human vascular smooth muscle cells</article-title><source>Cardiovasc Res</source><year>2013</year><volume>99</volume><issue>3</issue><fpage>505</fpage><lpage>513</lpage><pub-id pub-id-type="doi">10.1093/cvr/cvt112</pub-id><pub-id pub-id-type="pmid">23658376</pub-id>
</element-citation><mixed-citation id="mc-CR13" publication-type="journal">Bohm A, Flosser A, Ermler S, Fender AC, Luth A, Kleuser B et al (2013) Factor-Xa-induced mitogenesis and migration require sphingosine kinase activity and S1P formation in human vascular smooth muscle cells. Cardiovasc Res 99(3):505&#x02013;513<pub-id pub-id-type="pmid">23658376</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name><surname>Bu</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>H</given-names></name><name><surname>Deng</surname><given-names>R</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name></person-group><article-title>Therapeutic potential of SphK1 inhibitors based on abnormal expression of sphk1 in inflammatory immune related-diseases</article-title><source>Front Pharmacol</source><year>2021</year><volume>12</volume><fpage>733387</fpage><pub-id pub-id-type="doi">10.3389/fphar.2021.733387</pub-id><pub-id pub-id-type="pmid">34737701</pub-id>
</element-citation><mixed-citation id="mc-CR14" publication-type="journal">Bu Y, Wu H, Deng R, Wang Y (2021) Therapeutic potential of SphK1 inhibitors based on abnormal expression of sphk1 in inflammatory immune related-diseases. Front Pharmacol 12:733387<pub-id pub-id-type="pmid">34737701</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name><surname>Burow</surname><given-names>P</given-names></name><name><surname>Klapperstuck</surname><given-names>M</given-names></name><name><surname>Markwardt</surname><given-names>F</given-names></name></person-group><article-title>Activation of ATP secretion via volume-regulated anion channels by sphingosine-1-phosphate in RAW macrophages</article-title><source>Pflugers Arch</source><year>2015</year><volume>467</volume><issue>6</issue><fpage>1215</fpage><lpage>1226</lpage><pub-id pub-id-type="doi">10.1007/s00424-014-1561-8</pub-id><pub-id pub-id-type="pmid">24965069</pub-id>
</element-citation><mixed-citation id="mc-CR15" publication-type="journal">Burow P, Klapperstuck M, Markwardt F (2015) Activation of ATP secretion via volume-regulated anion channels by sphingosine-1-phosphate in RAW macrophages. Pflugers Arch 467(6):1215&#x02013;1226<pub-id pub-id-type="pmid">24965069</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Lockett</surname><given-names>A</given-names></name><name><surname>Zhao</surname><given-names>S</given-names></name><name><surname>Huang</surname><given-names>LS</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>W</given-names></name><etal/></person-group><article-title>Sphingosine kinase 1 deficiency in smooth muscle cells protects against hypoxia-mediated pulmonary hypertension via YAP1 signaling</article-title><source>Int J Mol Sci</source><year>2022</year><volume>23</volume><issue>23</issue><fpage>14516</fpage><pub-id pub-id-type="doi">10.3390/ijms232314516</pub-id><pub-id pub-id-type="pmid">36498853</pub-id>
</element-citation><mixed-citation id="mc-CR16" publication-type="journal">Chen J, Lockett A, Zhao S, Huang LS, Wang Y, Wu W et al (2022) Sphingosine kinase 1 deficiency in smooth muscle cells protects against hypoxia-mediated pulmonary hypertension via YAP1 signaling. Int J Mol Sci 23(23):14516<pub-id pub-id-type="pmid">36498853</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name><surname>Cobb</surname><given-names>AM</given-names></name><name><surname>Yusoff</surname><given-names>S</given-names></name><name><surname>Hayward</surname><given-names>R</given-names></name><name><surname>Ahmad</surname><given-names>S</given-names></name><name><surname>Sun</surname><given-names>M</given-names></name><name><surname>Verhulst</surname><given-names>A</given-names></name><etal/></person-group><article-title>Runx2 (runt-related transcription factor 2) links the DNA damage response to osteogenic reprogramming and apoptosis of vascular smooth muscle cells</article-title><source>Arterioscler Thromb Vasc Biol</source><year>2021</year><volume>41</volume><issue>4</issue><fpage>1339</fpage><lpage>1357</lpage><pub-id pub-id-type="doi">10.1161/ATVBAHA.120.315206</pub-id><pub-id pub-id-type="pmid">33356386</pub-id>
</element-citation><mixed-citation id="mc-CR17" publication-type="journal">Cobb AM, Yusoff S, Hayward R, Ahmad S, Sun M, Verhulst A et al (2021) Runx2 (runt-related transcription factor 2) links the DNA damage response to osteogenic reprogramming and apoptosis of vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 41(4):1339&#x02013;1357<pub-id pub-id-type="pmid">33356386</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name><surname>Durham</surname><given-names>AL</given-names></name><name><surname>Speer</surname><given-names>MY</given-names></name><name><surname>Scatena</surname><given-names>M</given-names></name><name><surname>Giachelli</surname><given-names>CM</given-names></name><name><surname>Shanahan</surname><given-names>CM</given-names></name></person-group><article-title>Role of smooth muscle cells in vascular calcification: implications in atherosclerosis and arterial stiffness</article-title><source>Cardiovasc Res</source><year>2018</year><volume>114</volume><issue>4</issue><fpage>590</fpage><lpage>600</lpage><pub-id pub-id-type="doi">10.1093/cvr/cvy010</pub-id><pub-id pub-id-type="pmid">29514202</pub-id>
</element-citation><mixed-citation id="mc-CR18" publication-type="journal">Durham AL, Speer MY, Scatena M, Giachelli CM, Shanahan CM (2018) Role of smooth muscle cells in vascular calcification: implications in atherosclerosis and arterial stiffness. Cardiovasc Res 114(4):590&#x02013;600<pub-id pub-id-type="pmid">29514202</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name><surname>Duse</surname><given-names>DA</given-names></name><name><surname>Schroder</surname><given-names>NH</given-names></name><name><surname>Srivastava</surname><given-names>T</given-names></name><name><surname>Benkhoff</surname><given-names>M</given-names></name><name><surname>Vogt</surname><given-names>J</given-names></name><name><surname>Nowak</surname><given-names>MK</given-names></name><etal/></person-group><article-title>Deficiency of the sphingosine-1-phosphate (S1P) transporter Mfsd2b protects the heart against hypertension-induced cardiac remodeling by suppressing the L-type-Ca(2+) channel</article-title><source>Basic Res Cardiol</source><year>2024</year><volume>119</volume><issue>5</issue><fpage>853</fpage><lpage>868</lpage><pub-id pub-id-type="doi">10.1007/s00395-024-01073-x</pub-id><pub-id pub-id-type="pmid">39110173</pub-id>
</element-citation><mixed-citation id="mc-CR19" publication-type="journal">Duse DA, Schroder NH, Srivastava T, Benkhoff M, Vogt J, Nowak MK et al (2024) Deficiency of the sphingosine-1-phosphate (S1P) transporter Mfsd2b protects the heart against hypertension-induced cardiac remodeling by suppressing the L-type-Ca(2+) channel. Basic Res Cardiol 119(5):853&#x02013;868<pub-id pub-id-type="pmid">39110173</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name><surname>Feuerborn</surname><given-names>R</given-names></name><name><surname>Besser</surname><given-names>M</given-names></name><name><surname>Poti</surname><given-names>F</given-names></name><name><surname>Burkhardt</surname><given-names>R</given-names></name><name><surname>Weissen-Plenz</surname><given-names>G</given-names></name><name><surname>Ceglarek</surname><given-names>U</given-names></name><etal/></person-group><article-title>Elevating endogenous sphingosine-1-phosphate (S1P) levels improves endothelial function and ameliorates atherosclerosis in low density lipoprotein receptor-deficient (LDL-R-/-) mice</article-title><source>Thromb Haemost</source><year>2018</year><volume>118</volume><issue>8</issue><fpage>1470</fpage><lpage>1480</lpage><pub-id pub-id-type="doi">10.1055/s-0038-1666870</pub-id><pub-id pub-id-type="pmid">30060257</pub-id>
</element-citation><mixed-citation id="mc-CR20" publication-type="journal">Feuerborn R, Besser M, Poti F, Burkhardt R, Weissen-Plenz G, Ceglarek U et al (2018) Elevating endogenous sphingosine-1-phosphate (S1P) levels improves endothelial function and ameliorates atherosclerosis in low density lipoprotein receptor-deficient (LDL-R-/-) mice. Thromb Haemost 118(8):1470&#x02013;1480<pub-id pub-id-type="pmid">30060257</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name><surname>Francy</surname><given-names>JM</given-names></name><name><surname>Nag</surname><given-names>A</given-names></name><name><surname>Conroy</surname><given-names>EJ</given-names></name><name><surname>Hengst</surname><given-names>JA</given-names></name><name><surname>Yun</surname><given-names>JK</given-names></name></person-group><article-title>Sphingosine kinase 1 expression is regulated by signaling through PI3K, AKT2, and mTOR in human coronary artery smooth muscle cells</article-title><source>Biochim Biophys Acta</source><year>2007</year><volume>1769</volume><issue>4</issue><fpage>253</fpage><lpage>265</lpage><pub-id pub-id-type="doi">10.1016/j.bbaexp.2007.03.005</pub-id><pub-id pub-id-type="pmid">17482291</pub-id>
</element-citation><mixed-citation id="mc-CR21" publication-type="journal">Francy JM, Nag A, Conroy EJ, Hengst JA, Yun JK (2007) Sphingosine kinase 1 expression is regulated by signaling through PI3K, AKT2, and mTOR in human coronary artery smooth muscle cells. Biochim Biophys Acta 1769(4):253&#x02013;265<pub-id pub-id-type="pmid">17482291</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name><surname>Fritzemeier</surname><given-names>R</given-names></name><name><surname>Foster</surname><given-names>D</given-names></name><name><surname>Peralta</surname><given-names>A</given-names></name><name><surname>Payette</surname><given-names>M</given-names></name><name><surname>Kharel</surname><given-names>Y</given-names></name><name><surname>Huang</surname><given-names>T</given-names></name><etal/></person-group><article-title>Discovery of in vivo active sphingosine-1-phosphate transporter (Spns2) inhibitors</article-title><source>J Med Chem</source><year>2022</year><volume>65</volume><issue>11</issue><fpage>7656</fpage><lpage>7681</lpage><pub-id pub-id-type="doi">10.1021/acs.jmedchem.1c02171</pub-id><pub-id pub-id-type="pmid">35609189</pub-id>
</element-citation><mixed-citation id="mc-CR22" publication-type="journal">Fritzemeier R, Foster D, Peralta A, Payette M, Kharel Y, Huang T et al (2022) Discovery of in vivo active sphingosine-1-phosphate transporter (Spns2) inhibitors. J Med Chem 65(11):7656&#x02013;7681<pub-id pub-id-type="pmid">35609189</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name><surname>Gonzalez-Fernandez</surname><given-names>B</given-names></name><name><surname>Sanchez</surname><given-names>DI</given-names></name><name><surname>Crespo</surname><given-names>I</given-names></name><name><surname>San-Miguel</surname><given-names>B</given-names></name><name><surname>Alvarez</surname><given-names>M</given-names></name><name><surname>Tunon</surname><given-names>MJ</given-names></name><etal/></person-group><article-title>Inhibition of the SphK1/S1P signaling pathway by melatonin in mice with liver fibrosis and human hepatic stellate cells</article-title><source>BioFactors</source><year>2017</year><volume>43</volume><issue>2</issue><fpage>272</fpage><lpage>282</lpage><pub-id pub-id-type="doi">10.1002/biof.1342</pub-id><pub-id pub-id-type="pmid">27801960</pub-id>
</element-citation><mixed-citation id="mc-CR23" publication-type="journal">Gonzalez-Fernandez B, Sanchez DI, Crespo I, San-Miguel B, Alvarez M, Tunon MJ et al (2017) Inhibition of the SphK1/S1P signaling pathway by melatonin in mice with liver fibrosis and human hepatic stellate cells. BioFactors 43(2):272&#x02013;282<pub-id pub-id-type="pmid">27801960</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name><surname>Gude</surname><given-names>DR</given-names></name><name><surname>Alvarez</surname><given-names>SE</given-names></name><name><surname>Paugh</surname><given-names>SW</given-names></name><name><surname>Mitra</surname><given-names>P</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Griffiths</surname><given-names>R</given-names></name><etal/></person-group><article-title>Apoptosis induces expression of sphingosine kinase 1 to release sphingosine-1-phosphate as a &#x0201c;come-and-get-me&#x0201d; signal</article-title><source>FASEB J</source><year>2008</year><volume>22</volume><issue>8</issue><fpage>2629</fpage><lpage>2638</lpage><pub-id pub-id-type="doi">10.1096/fj.08-107169</pub-id><pub-id pub-id-type="pmid">18362204</pub-id>
</element-citation><mixed-citation id="mc-CR24" publication-type="journal">Gude DR, Alvarez SE, Paugh SW, Mitra P, Yu J, Griffiths R et al (2008) Apoptosis induces expression of sphingosine kinase 1 to release sphingosine-1-phosphate as a &#x0201c;come-and-get-me&#x0201d; signal. FASEB J 22(8):2629&#x02013;2638<pub-id pub-id-type="pmid">18362204</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name><surname>Hait</surname><given-names>NC</given-names></name><name><surname>Allegood</surname><given-names>J</given-names></name><name><surname>Maceyka</surname><given-names>M</given-names></name><name><surname>Strub</surname><given-names>GM</given-names></name><name><surname>Harikumar</surname><given-names>KB</given-names></name><name><surname>Singh</surname><given-names>SK</given-names></name><etal/></person-group><article-title>Regulation of histone acetylation in the nucleus by sphingosine-1-phosphate</article-title><source>Science</source><year>2009</year><volume>325</volume><issue>5945</issue><fpage>1254</fpage><lpage>1257</lpage><pub-id pub-id-type="doi">10.1126/science.1176709</pub-id><pub-id pub-id-type="pmid">19729656</pub-id>
</element-citation><mixed-citation id="mc-CR25" publication-type="journal">Hait NC, Allegood J, Maceyka M, Strub GM, Harikumar KB, Singh SK et al (2009) Regulation of histone acetylation in the nucleus by sphingosine-1-phosphate. Science 325(5945):1254&#x02013;1257<pub-id pub-id-type="pmid">19729656</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name><surname>Hammer</surname><given-names>F</given-names></name><name><surname>Buehling</surname><given-names>SS</given-names></name><name><surname>Masyout</surname><given-names>J</given-names></name><name><surname>Malzahn</surname><given-names>U</given-names></name><name><surname>Hauser</surname><given-names>T</given-names></name><name><surname>Auer</surname><given-names>T</given-names></name><etal/></person-group><article-title>Protective effects of spironolactone on vascular calcification in chronic kidney disease</article-title><source>Biochem Biophys Res Commun</source><year>2021</year><volume>582</volume><fpage>28</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2021.10.023</pub-id><pub-id pub-id-type="pmid">34678593</pub-id>
</element-citation><mixed-citation id="mc-CR26" publication-type="journal">Hammer F, Buehling SS, Masyout J, Malzahn U, Hauser T, Auer T et al (2021) Protective effects of spironolactone on vascular calcification in chronic kidney disease. Biochem Biophys Res Commun 582:28&#x02013;34<pub-id pub-id-type="pmid">34678593</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name><surname>Harikumar</surname><given-names>KB</given-names></name><name><surname>Yester</surname><given-names>JW</given-names></name><name><surname>Surace</surname><given-names>MJ</given-names></name><name><surname>Oyeniran</surname><given-names>C</given-names></name><name><surname>Price</surname><given-names>MM</given-names></name><name><surname>Huang</surname><given-names>WC</given-names></name><etal/></person-group><article-title>K63-linked polyubiquitination of transcription factor IRF1 is essential for IL-1-induced production of chemokines CXCL10 and CCL5</article-title><source>Nat Immunol</source><year>2014</year><volume>15</volume><issue>3</issue><fpage>231</fpage><lpage>238</lpage><pub-id pub-id-type="doi">10.1038/ni.2810</pub-id><pub-id pub-id-type="pmid">24464131</pub-id>
</element-citation><mixed-citation id="mc-CR27" publication-type="journal">Harikumar KB, Yester JW, Surace MJ, Oyeniran C, Price MM, Huang WC et al (2014) K63-linked polyubiquitination of transcription factor IRF1 is essential for IL-1-induced production of chemokines CXCL10 and CCL5. Nat Immunol 15(3):231&#x02013;238<pub-id pub-id-type="pmid">24464131</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name><surname>Henze</surname><given-names>LA</given-names></name><name><surname>Luong</surname><given-names>TTD</given-names></name><name><surname>Boehme</surname><given-names>B</given-names></name><name><surname>Masyout</surname><given-names>J</given-names></name><name><surname>Schneider</surname><given-names>MP</given-names></name><name><surname>Brachs</surname><given-names>S</given-names></name><etal/></person-group><article-title>Impact of C-reactive protein on osteo-/chondrogenic transdifferentiation and calcification of vascular smooth muscle cells</article-title><source>Aging (Albany NY)</source><year>2019</year><volume>11</volume><issue>15</issue><fpage>5445</fpage><lpage>5462</lpage><pub-id pub-id-type="doi">10.18632/aging.102130</pub-id><pub-id pub-id-type="pmid">31377747</pub-id>
</element-citation><mixed-citation id="mc-CR28" publication-type="journal">Henze LA, Luong TTD, Boehme B, Masyout J, Schneider MP, Brachs S et al (2019) Impact of C-reactive protein on osteo-/chondrogenic transdifferentiation and calcification of vascular smooth muscle cells. Aging (Albany NY) 11(15):5445&#x02013;5462<pub-id pub-id-type="pmid">31377747</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name><surname>Herrmann</surname><given-names>J</given-names></name><name><surname>Gummi</surname><given-names>MR</given-names></name><name><surname>Xia</surname><given-names>M</given-names></name><name><surname>van der Giet</surname><given-names>M</given-names></name><name><surname>Tolle</surname><given-names>M</given-names></name><name><surname>Schuchardt</surname><given-names>M</given-names></name></person-group><article-title>Vascular calcification in rodent models-keeping track with an extented method assortment</article-title><source>Biology (Basel)</source><year>2021</year><volume>10</volume><issue>6</issue><fpage>459</fpage><pub-id pub-id-type="pmid">34067504</pub-id>
</element-citation><mixed-citation id="mc-CR29" publication-type="journal">Herrmann J, Gummi MR, Xia M, van der Giet M, Tolle M, Schuchardt M (2021) Vascular calcification in rodent models-keeping track with an extented method assortment. Biology (Basel) 10(6):459<pub-id pub-id-type="pmid">34067504</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name><surname>Hisano</surname><given-names>Y</given-names></name><name><surname>Kobayashi</surname><given-names>N</given-names></name><name><surname>Yamaguchi</surname><given-names>A</given-names></name><name><surname>Nishi</surname><given-names>T</given-names></name></person-group><article-title>Mouse SPNS2 functions as a sphingosine-1-phosphate transporter in vascular endothelial cells</article-title><source>PLoS ONE</source><year>2012</year><volume>7</volume><issue>6</issue><fpage>e38941</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0038941</pub-id><pub-id pub-id-type="pmid">22723910</pub-id>
</element-citation><mixed-citation id="mc-CR30" publication-type="journal">Hisano Y, Kobayashi N, Yamaguchi A, Nishi T (2012) Mouse SPNS2 functions as a sphingosine-1-phosphate transporter in vascular endothelial cells. PLoS ONE 7(6):e38941<pub-id pub-id-type="pmid">22723910</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>J</given-names></name><name><surname>Huang</surname><given-names>H</given-names></name><name><surname>Wu</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Xie</surname><given-names>H</given-names></name><name><surname>Zhou</surname><given-names>H</given-names></name><etal/></person-group><article-title>Connective tissue growth factor induces osteogenic differentiation of vascular smooth muscle cells through ERK signaling</article-title><source>Int J Mol Med</source><year>2013</year><volume>32</volume><issue>2</issue><fpage>423</fpage><lpage>429</lpage><pub-id pub-id-type="doi">10.3892/ijmm.2013.1398</pub-id><pub-id pub-id-type="pmid">23722620</pub-id>
</element-citation><mixed-citation id="mc-CR31" publication-type="journal">Huang J, Huang H, Wu M, Li J, Xie H, Zhou H et al (2013) Connective tissue growth factor induces osteogenic differentiation of vascular smooth muscle cells through ERK signaling. Int J Mol Med 32(2):423&#x02013;429<pub-id pub-id-type="pmid">23722620</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name><surname>Ishimaru</surname><given-names>K</given-names></name><name><surname>Yoshioka</surname><given-names>K</given-names></name><name><surname>Kano</surname><given-names>K</given-names></name><name><surname>Kurano</surname><given-names>M</given-names></name><name><surname>Saigusa</surname><given-names>D</given-names></name><name><surname>Aoki</surname><given-names>J</given-names></name><etal/></person-group><article-title>Sphingosine kinase-2 prevents macrophage cholesterol accumulation and atherosclerosis by stimulating autophagic lipid degradation</article-title><source>Sci Rep</source><year>2019</year><volume>9</volume><issue>1</issue><fpage>18329</fpage><pub-id pub-id-type="doi">10.1038/s41598-019-54877-6</pub-id><pub-id pub-id-type="pmid">31797978</pub-id>
</element-citation><mixed-citation id="mc-CR32" publication-type="journal">Ishimaru K, Yoshioka K, Kano K, Kurano M, Saigusa D, Aoki J et al (2019) Sphingosine kinase-2 prevents macrophage cholesterol accumulation and atherosclerosis by stimulating autophagic lipid degradation. Sci Rep 9(1):18329<pub-id pub-id-type="pmid">31797978</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name><surname>Jono</surname><given-names>S</given-names></name><name><surname>McKee</surname><given-names>MD</given-names></name><name><surname>Murry</surname><given-names>CE</given-names></name><name><surname>Shioi</surname><given-names>A</given-names></name><name><surname>Nishizawa</surname><given-names>Y</given-names></name><name><surname>Mori</surname><given-names>K</given-names></name><etal/></person-group><article-title>Phosphate regulation of vascular smooth muscle cell calcification</article-title><source>Circ Res</source><year>2000</year><volume>87</volume><issue>7</issue><fpage>E10</fpage><lpage>E17</lpage><pub-id pub-id-type="doi">10.1161/01.RES.87.7.e10</pub-id><pub-id pub-id-type="pmid">11009570</pub-id>
</element-citation><mixed-citation id="mc-CR33" publication-type="journal">Jono S, McKee MD, Murry CE, Shioi A, Nishizawa Y, Mori K et al (2000) Phosphate regulation of vascular smooth muscle cell calcification. Circ Res 87(7):E10&#x02013;E17<pub-id pub-id-type="pmid">11009570</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name><surname>Jozefczuk</surname><given-names>E</given-names></name><name><surname>Guzik</surname><given-names>TJ</given-names></name><name><surname>Siedlinski</surname><given-names>M</given-names></name></person-group><article-title>Significance of sphingosine-1-phosphate in cardiovascular physiology and pathology</article-title><source>Pharmacol Res</source><year>2020</year><volume>156</volume><fpage>104793</fpage><pub-id pub-id-type="doi">10.1016/j.phrs.2020.104793</pub-id><pub-id pub-id-type="pmid">32278039</pub-id>
</element-citation><mixed-citation id="mc-CR34" publication-type="journal">Jozefczuk E, Guzik TJ, Siedlinski M (2020) Significance of sphingosine-1-phosphate in cardiovascular physiology and pathology. Pharmacol Res 156:104793<pub-id pub-id-type="pmid">32278039</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name><surname>Karaca</surname><given-names>I</given-names></name><name><surname>Tamboli</surname><given-names>IY</given-names></name><name><surname>Glebov</surname><given-names>K</given-names></name><name><surname>Richter</surname><given-names>J</given-names></name><name><surname>Fell</surname><given-names>LH</given-names></name><name><surname>Grimm</surname><given-names>MO</given-names></name><etal/></person-group><article-title>Deficiency of sphingosine-1-phosphate lyase impairs lysosomal metabolism of the amyloid precursor protein</article-title><source>J Biol Chem</source><year>2014</year><volume>289</volume><issue>24</issue><fpage>16761</fpage><lpage>16772</lpage><pub-id pub-id-type="doi">10.1074/jbc.M113.535500</pub-id><pub-id pub-id-type="pmid">24808180</pub-id>
</element-citation><mixed-citation id="mc-CR35" publication-type="journal">Karaca I, Tamboli IY, Glebov K, Richter J, Fell LH, Grimm MO et al (2014) Deficiency of sphingosine-1-phosphate lyase impairs lysosomal metabolism of the amyloid precursor protein. J Biol Chem 289(24):16761&#x02013;16772<pub-id pub-id-type="pmid">24808180</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name><surname>Kerage</surname><given-names>D</given-names></name><name><surname>Gombos</surname><given-names>RB</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Brown</surname><given-names>M</given-names></name><name><surname>Hemmings</surname><given-names>DG</given-names></name></person-group><article-title>Sphingosine 1-phosphate-induced nitric oxide production simultaneously controls endothelial barrier function and vascular tone in resistance arteries</article-title><source>Vascul Pharmacol</source><year>2021</year><volume>140</volume><fpage>106874</fpage><pub-id pub-id-type="doi">10.1016/j.vph.2021.106874</pub-id><pub-id pub-id-type="pmid">34004349</pub-id>
</element-citation><mixed-citation id="mc-CR36" publication-type="journal">Kerage D, Gombos RB, Wang S, Brown M, Hemmings DG (2021) Sphingosine 1-phosphate-induced nitric oxide production simultaneously controls endothelial barrier function and vascular tone in resistance arteries. Vascul Pharmacol 140:106874<pub-id pub-id-type="pmid">34004349</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name><surname>Keul</surname><given-names>P</given-names></name><name><surname>Peters</surname><given-names>S</given-names></name><name><surname>von Wnuck Lipinski</surname><given-names>K</given-names></name><name><surname>Schroder</surname><given-names>NH</given-names></name><name><surname>Nowak</surname><given-names>MK</given-names></name><name><surname>Duse</surname><given-names>DA</given-names></name><etal/></person-group><article-title>Sphingosine-1-phosphate (S1P) lyase inhibition aggravates atherosclerosis and induces plaque rupture in ApoE(-/-) mice</article-title><source>Int J Mol Sci</source><year>2022</year><volume>23</volume><issue>17</issue><fpage>9606</fpage><pub-id pub-id-type="doi">10.3390/ijms23179606</pub-id><pub-id pub-id-type="pmid">36077004</pub-id>
</element-citation><mixed-citation id="mc-CR37" publication-type="journal">Keul P, Peters S, von Wnuck Lipinski K, Schroder NH, Nowak MK, Duse DA et al (2022) Sphingosine-1-phosphate (S1P) lyase inhibition aggravates atherosclerosis and induces plaque rupture in ApoE(-/-) mice. Int J Mol Sci 23(17):9606<pub-id pub-id-type="pmid">36077004</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name><surname>Koch</surname><given-names>A</given-names></name><name><surname>Pfeilschifter</surname><given-names>J</given-names></name><name><surname>Huwiler</surname><given-names>A</given-names></name></person-group><article-title>Sphingosine 1-phosphate in renal diseases</article-title><source>Cell Physiol Biochem</source><year>2013</year><volume>31</volume><issue>6</issue><fpage>745</fpage><lpage>760</lpage><pub-id pub-id-type="doi">10.1159/000350093</pub-id><pub-id pub-id-type="pmid">23736205</pub-id>
</element-citation><mixed-citation id="mc-CR38" publication-type="journal">Koch A, Pfeilschifter J, Huwiler A (2013) Sphingosine 1-phosphate in renal diseases. Cell Physiol Biochem 31(6):745&#x02013;760<pub-id pub-id-type="pmid">23736205</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name><surname>Lanzer</surname><given-names>P</given-names></name><name><surname>Hannan</surname><given-names>FM</given-names></name><name><surname>Lanzer</surname><given-names>JD</given-names></name><name><surname>Janzen</surname><given-names>J</given-names></name><name><surname>Raggi</surname><given-names>P</given-names></name><name><surname>Furniss</surname><given-names>D</given-names></name><etal/></person-group><article-title>Medial arterial calcification: JACC state-of-the-art review</article-title><source>J Am Coll Cardiol</source><year>2021</year><volume>78</volume><issue>11</issue><fpage>1145</fpage><lpage>1165</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2021.06.049</pub-id><pub-id pub-id-type="pmid">34503684</pub-id>
</element-citation><mixed-citation id="mc-CR39" publication-type="journal">Lanzer P, Hannan FM, Lanzer JD, Janzen J, Raggi P, Furniss D et al (2021) Medial arterial calcification: JACC state-of-the-art review. J Am Coll Cardiol 78(11):1145&#x02013;1165<pub-id pub-id-type="pmid">34503684</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>F</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Zhu</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Feng</surname><given-names>W</given-names></name><name><surname>Shi</surname><given-names>W</given-names></name><etal/></person-group><article-title>SphK1/S1P mediates PDGF-induced pulmonary arterial smooth muscle cell proliferation via miR-21/BMPRII/Id1 signaling pathway</article-title><source>Cell Physiol Biochem</source><year>2018</year><volume>51</volume><issue>1</issue><fpage>487</fpage><lpage>500</lpage><pub-id pub-id-type="doi">10.1159/000495243</pub-id><pub-id pub-id-type="pmid">30453304</pub-id>
</element-citation><mixed-citation id="mc-CR40" publication-type="journal">Li F, Wang J, Zhu Y, Liu L, Feng W, Shi W et al (2018) SphK1/S1P mediates PDGF-induced pulmonary arterial smooth muscle cell proliferation via miR-21/BMPRII/Id1 signaling pathway. Cell Physiol Biochem 51(1):487&#x02013;500<pub-id pub-id-type="pmid">30453304</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name><surname>Liao</surname><given-names>YR</given-names></name><name><surname>Tsai</surname><given-names>YC</given-names></name><name><surname>Hsieh</surname><given-names>TH</given-names></name><name><surname>Tsai</surname><given-names>MT</given-names></name><name><surname>Lin</surname><given-names>FY</given-names></name><name><surname>Lin</surname><given-names>SJ</given-names></name><etal/></person-group><article-title>FHL2 in arterial medial calcification in chronic kidney disease</article-title><source>Nephrol Dial Transplant</source><year>2024</year><volume>39</volume><issue>12</issue><fpage>2025</fpage><lpage>2039</lpage><pub-id pub-id-type="doi">10.1093/ndt/gfae091</pub-id><pub-id pub-id-type="pmid">38664060</pub-id>
</element-citation><mixed-citation id="mc-CR41" publication-type="journal">Liao YR, Tsai YC, Hsieh TH, Tsai MT, Lin FY, Lin SJ et al (2024) FHL2 in arterial medial calcification in chronic kidney disease. Nephrol Dial Transplant 39(12):2025&#x02013;2039<pub-id pub-id-type="pmid">38664060</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR42"><label>42.</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>ME</given-names></name><name><surname>Chen</surname><given-names>T</given-names></name><name><surname>Leaf</surname><given-names>EM</given-names></name><name><surname>Speer</surname><given-names>MY</given-names></name><name><surname>Giachelli</surname><given-names>CM</given-names></name></person-group><article-title>Runx2 expression in smooth muscle cells is required for arterial medial calcification in mice</article-title><source>Am J Pathol</source><year>2015</year><volume>185</volume><issue>7</issue><fpage>1958</fpage><lpage>1969</lpage><pub-id pub-id-type="doi">10.1016/j.ajpath.2015.03.020</pub-id><pub-id pub-id-type="pmid">25987250</pub-id>
</element-citation><mixed-citation id="mc-CR42" publication-type="journal">Lin ME, Chen T, Leaf EM, Speer MY, Giachelli CM (2015) Runx2 expression in smooth muscle cells is required for arterial medial calcification in mice. Am J Pathol 185(7):1958&#x02013;1969<pub-id pub-id-type="pmid">25987250</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR43"><label>43.</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name><surname>Luong</surname><given-names>TTD</given-names></name><name><surname>Tuffaha</surname><given-names>R</given-names></name><name><surname>Schuchardt</surname><given-names>M</given-names></name><name><surname>Moser</surname><given-names>B</given-names></name><name><surname>Schelski</surname><given-names>N</given-names></name><name><surname>Boehme</surname><given-names>B</given-names></name><etal/></person-group><article-title>Acid sphingomyelinase promotes SGK1-dependent vascular calcification</article-title><source>Clin Sci (Lond)</source><year>2021</year><volume>135</volume><issue>3</issue><fpage>515</fpage><lpage>534</lpage><pub-id pub-id-type="doi">10.1042/CS20201122</pub-id><pub-id pub-id-type="pmid">33479769</pub-id>
</element-citation><mixed-citation id="mc-CR43" publication-type="journal">Luong TTD, Tuffaha R, Schuchardt M, Moser B, Schelski N, Boehme B et al (2021) Acid sphingomyelinase promotes SGK1-dependent vascular calcification. Clin Sci (Lond) 135(3):515&#x02013;534<pub-id pub-id-type="pmid">33479769</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR44"><label>44.</label><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name><surname>Maceyka</surname><given-names>M</given-names></name><name><surname>Sankala</surname><given-names>H</given-names></name><name><surname>Hait</surname><given-names>NC</given-names></name><name><surname>Le Stunff</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Toman</surname><given-names>R</given-names></name><etal/></person-group><article-title>SphK1 and SphK2, sphingosine kinase isoenzymes with opposing functions in sphingolipid metabolism</article-title><source>J Biol Chem</source><year>2005</year><volume>280</volume><issue>44</issue><fpage>37118</fpage><lpage>37129</lpage><pub-id pub-id-type="doi">10.1074/jbc.M502207200</pub-id><pub-id pub-id-type="pmid">16118219</pub-id>
</element-citation><mixed-citation id="mc-CR44" publication-type="journal">Maceyka M, Sankala H, Hait NC, Le Stunff H, Liu H, Toman R et al (2005) SphK1 and SphK2, sphingosine kinase isoenzymes with opposing functions in sphingolipid metabolism. J Biol Chem 280(44):37118&#x02013;37129<pub-id pub-id-type="pmid">16118219</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR45"><label>45.</label><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name><surname>Mizugishi</surname><given-names>K</given-names></name><name><surname>Yamashita</surname><given-names>T</given-names></name><name><surname>Olivera</surname><given-names>A</given-names></name><name><surname>Miller</surname><given-names>GF</given-names></name><name><surname>Spiegel</surname><given-names>S</given-names></name><name><surname>Proia</surname><given-names>RL</given-names></name></person-group><article-title>Essential role for sphingosine kinases in neural and vascular development</article-title><source>Mol Cell Biol</source><year>2005</year><volume>25</volume><issue>24</issue><fpage>11113</fpage><lpage>11121</lpage><pub-id pub-id-type="doi">10.1128/MCB.25.24.11113-11121.2005</pub-id><pub-id pub-id-type="pmid">16314531</pub-id>
</element-citation><mixed-citation id="mc-CR45" publication-type="journal">Mizugishi K, Yamashita T, Olivera A, Miller GF, Spiegel S, Proia RL (2005) Essential role for sphingosine kinases in neural and vascular development. Mol Cell Biol 25(24):11113&#x02013;11121<pub-id pub-id-type="pmid">16314531</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR46"><label>46.</label><citation-alternatives><element-citation id="ec-CR46" publication-type="journal"><person-group person-group-type="author"><name><surname>Morris</surname><given-names>TG</given-names></name><name><surname>Borland</surname><given-names>SJ</given-names></name><name><surname>Clarke</surname><given-names>CJ</given-names></name><name><surname>Wilson</surname><given-names>C</given-names></name><name><surname>Hannun</surname><given-names>YA</given-names></name><name><surname>Ohanian</surname><given-names>V</given-names></name><etal/></person-group><article-title>Sphingosine 1-phosphate activation of ERM contributes to vascular calcification</article-title><source>J Lipid Res</source><year>2018</year><volume>59</volume><issue>1</issue><fpage>69</fpage><lpage>78</lpage><pub-id pub-id-type="doi">10.1194/jlr.M079731</pub-id><pub-id pub-id-type="pmid">29167409</pub-id>
</element-citation><mixed-citation id="mc-CR46" publication-type="journal">Morris TG, Borland SJ, Clarke CJ, Wilson C, Hannun YA, Ohanian V et al (2018) Sphingosine 1-phosphate activation of ERM contributes to vascular calcification. J Lipid Res 59(1):69&#x02013;78<pub-id pub-id-type="pmid">29167409</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR47"><label>47.</label><citation-alternatives><element-citation id="ec-CR47" publication-type="journal"><person-group person-group-type="author"><name><surname>Moser</surname><given-names>B</given-names></name><name><surname>Poetsch</surname><given-names>F</given-names></name><name><surname>Estepa</surname><given-names>M</given-names></name><name><surname>Luong</surname><given-names>TTD</given-names></name><name><surname>Pieske</surname><given-names>B</given-names></name><name><surname>Lang</surname><given-names>F</given-names></name><etal/></person-group><article-title>Increased beta-adrenergic stimulation augments vascular smooth muscle cell calcification via PKA/CREB signalling</article-title><source>Pflugers Arch</source><year>2021</year><volume>473</volume><issue>12</issue><fpage>1899</fpage><lpage>1910</lpage><pub-id pub-id-type="doi">10.1007/s00424-021-02621-3</pub-id><pub-id pub-id-type="pmid">34564739</pub-id>
</element-citation><mixed-citation id="mc-CR47" publication-type="journal">Moser B, Poetsch F, Estepa M, Luong TTD, Pieske B, Lang F et al (2021) Increased beta-adrenergic stimulation augments vascular smooth muscle cell calcification via PKA/CREB signalling. Pflugers Arch 473(12):1899&#x02013;1910<pub-id pub-id-type="pmid">34564739</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR48"><label>48.</label><citation-alternatives><element-citation id="ec-CR48" publication-type="journal"><person-group person-group-type="author"><name><surname>Newton</surname><given-names>J</given-names></name><name><surname>Lima</surname><given-names>S</given-names></name><name><surname>Maceyka</surname><given-names>M</given-names></name><name><surname>Spiegel</surname><given-names>S</given-names></name></person-group><article-title>Revisiting the sphingolipid rheostat: evolving concepts in cancer therapy</article-title><source>Exp Cell Res</source><year>2015</year><volume>333</volume><issue>2</issue><fpage>195</fpage><lpage>200</lpage><pub-id pub-id-type="doi">10.1016/j.yexcr.2015.02.025</pub-id><pub-id pub-id-type="pmid">25770011</pub-id>
</element-citation><mixed-citation id="mc-CR48" publication-type="journal">Newton J, Lima S, Maceyka M, Spiegel S (2015) Revisiting the sphingolipid rheostat: evolving concepts in cancer therapy. Exp Cell Res 333(2):195&#x02013;200<pub-id pub-id-type="pmid">25770011</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR49"><label>49.</label><citation-alternatives><element-citation id="ec-CR49" publication-type="journal"><person-group person-group-type="author"><name><surname>Parham</surname><given-names>KA</given-names></name><name><surname>Zebol</surname><given-names>JR</given-names></name><name><surname>Tooley</surname><given-names>KL</given-names></name><name><surname>Sun</surname><given-names>WY</given-names></name><name><surname>Moldenhauer</surname><given-names>LM</given-names></name><name><surname>Cockshell</surname><given-names>MP</given-names></name><etal/></person-group><article-title>Sphingosine 1-phosphate is a ligand for peroxisome proliferator-activated receptor-gamma that regulates neoangiogenesis</article-title><source>Faseb J</source><year>2015</year><volume>29</volume><issue>9</issue><fpage>3638</fpage><lpage>3653</lpage><pub-id pub-id-type="doi">10.1096/fj.14-261289</pub-id><pub-id pub-id-type="pmid">25985799</pub-id>
</element-citation><mixed-citation id="mc-CR49" publication-type="journal">Parham KA, Zebol JR, Tooley KL, Sun WY, Moldenhauer LM, Cockshell MP et al (2015) Sphingosine 1-phosphate is a ligand for peroxisome proliferator-activated receptor-gamma that regulates neoangiogenesis. Faseb J 29(9):3638&#x02013;3653<pub-id pub-id-type="pmid">25985799</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR50"><label>50.</label><citation-alternatives><element-citation id="ec-CR50" publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>ES</given-names></name><name><surname>Choi</surname><given-names>S</given-names></name><name><surname>Shin</surname><given-names>B</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Hwang</surname><given-names>JM</given-names></name><etal/></person-group><article-title>Tumor necrosis factor (TNF) receptor-associated factor (TRAF)-interacting protein (TRIP) negatively regulates the TRAF2 ubiquitin-dependent pathway by suppressing the TRAF2-sphingosine 1-phosphate (S1P) interaction</article-title><source>J Biol Chem</source><year>2015</year><volume>290</volume><issue>15</issue><fpage>9660</fpage><lpage>9673</lpage><pub-id pub-id-type="doi">10.1074/jbc.M114.609685</pub-id><pub-id pub-id-type="pmid">25716317</pub-id>
</element-citation><mixed-citation id="mc-CR50" publication-type="journal">Park ES, Choi S, Shin B, Yu J, Yu J, Hwang JM et al (2015) Tumor necrosis factor (TNF) receptor-associated factor (TRAF)-interacting protein (TRIP) negatively regulates the TRAF2 ubiquitin-dependent pathway by suppressing the TRAF2-sphingosine 1-phosphate (S1P) interaction. J Biol Chem 290(15):9660&#x02013;9673<pub-id pub-id-type="pmid">25716317</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR51"><label>51.</label><citation-alternatives><element-citation id="ec-CR51" publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>K</given-names></name><name><surname>Ikushiro</surname><given-names>H</given-names></name><name><surname>Seo</surname><given-names>HS</given-names></name><name><surname>Shin</surname><given-names>KO</given-names></name><name><surname>Kim</surname><given-names>YI</given-names></name><name><surname>Kim</surname><given-names>JY</given-names></name><etal/></person-group><article-title>ER stress stimulates production of the key antimicrobial peptide, cathelicidin, by forming a previously unidentified intracellular S1P signaling complex</article-title><source>Proc Natl Acad Sci U S A</source><year>2016</year><volume>113</volume><issue>10</issue><fpage>E1334</fpage><lpage>E1342</lpage><pub-id pub-id-type="doi">10.1073/pnas.1504555113</pub-id><pub-id pub-id-type="pmid">26903652</pub-id>
</element-citation><mixed-citation id="mc-CR51" publication-type="journal">Park K, Ikushiro H, Seo HS, Shin KO, Kim YI, Kim JY et al (2016) ER stress stimulates production of the key antimicrobial peptide, cathelicidin, by forming a previously unidentified intracellular S1P signaling complex. Proc Natl Acad Sci U S A 113(10):E1334&#x02013;E1342<pub-id pub-id-type="pmid">26903652</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR52"><label>52.</label><mixed-citation publication-type="other">Pavlic A, Poelman H, Wasilewski G, Wichapong K, Lux P, Maassen C, et al (2023) Inhibition of neutral sphingomyelinase 2 by novel small molecule inhibitors results in decreased release of extracellular vesicles by vascular smooth muscle cells and attenuated calcification. Int J Mol Sci 24(3)</mixed-citation></ref><ref id="CR53"><label>53.</label><citation-alternatives><element-citation id="ec-CR53" publication-type="journal"><person-group person-group-type="author"><name><surname>Poetsch</surname><given-names>F</given-names></name><name><surname>Henze</surname><given-names>LA</given-names></name><name><surname>Estepa</surname><given-names>M</given-names></name><name><surname>Moser</surname><given-names>B</given-names></name><name><surname>Pieske</surname><given-names>B</given-names></name><name><surname>Lang</surname><given-names>F</given-names></name><etal/></person-group><article-title>Role of SGK1 in the osteogenic transdifferentiation and calcification of vascular smooth muscle cells promoted by hyperglycemic conditions</article-title><source>Int J Mol Sci</source><year>2020</year><volume>21</volume><issue>19</issue><fpage>7207</fpage><pub-id pub-id-type="doi">10.3390/ijms21197207</pub-id><pub-id pub-id-type="pmid">33003561</pub-id>
</element-citation><mixed-citation id="mc-CR53" publication-type="journal">Poetsch F, Henze LA, Estepa M, Moser B, Pieske B, Lang F et al (2020) Role of SGK1 in the osteogenic transdifferentiation and calcification of vascular smooth muscle cells promoted by hyperglycemic conditions. Int J Mol Sci 21(19):7207<pub-id pub-id-type="pmid">33003561</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR54"><label>54.</label><citation-alternatives><element-citation id="ec-CR54" publication-type="journal"><person-group person-group-type="author"><name><surname>Poti</surname><given-names>F</given-names></name><name><surname>Bot</surname><given-names>M</given-names></name><name><surname>Costa</surname><given-names>S</given-names></name><name><surname>Bergonzini</surname><given-names>V</given-names></name><name><surname>Maines</surname><given-names>L</given-names></name><name><surname>Varga</surname><given-names>G</given-names></name><etal/></person-group><article-title>Sphingosine kinase inhibition exerts both pro- and anti-atherogenic effects in low-density lipoprotein receptor-deficient (LDL-R(-/-)) mice</article-title><source>Thromb Haemost</source><year>2012</year><volume>107</volume><issue>3</issue><fpage>552</fpage><lpage>561</lpage><pub-id pub-id-type="doi">10.1160/TH11-08-0583</pub-id><pub-id pub-id-type="pmid">22234485</pub-id>
</element-citation><mixed-citation id="mc-CR54" publication-type="journal">Poti F, Bot M, Costa S, Bergonzini V, Maines L, Varga G et al (2012) Sphingosine kinase inhibition exerts both pro- and anti-atherogenic effects in low-density lipoprotein receptor-deficient (LDL-R(-/-)) mice. Thromb Haemost 107(3):552&#x02013;561<pub-id pub-id-type="pmid">22234485</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR55"><label>55.</label><citation-alternatives><element-citation id="ec-CR55" publication-type="journal"><person-group person-group-type="author"><name><surname>Poti</surname><given-names>F</given-names></name><name><surname>Ceglarek</surname><given-names>U</given-names></name><name><surname>Burkhardt</surname><given-names>R</given-names></name><name><surname>Simoni</surname><given-names>M</given-names></name><name><surname>Nofer</surname><given-names>JR</given-names></name></person-group><article-title>SKI-II&#x02013;a sphingosine kinase 1 inhibitor&#x02013;exacerbates atherosclerosis in low-density lipoprotein receptor-deficient (LDL-R-/-) mice on high cholesterol diet</article-title><source>Atherosclerosis</source><year>2015</year><volume>240</volume><issue>1</issue><fpage>212</fpage><lpage>215</lpage><pub-id pub-id-type="doi">10.1016/j.atherosclerosis.2015.03.020</pub-id><pub-id pub-id-type="pmid">25801013</pub-id>
</element-citation><mixed-citation id="mc-CR55" publication-type="journal">Poti F, Ceglarek U, Burkhardt R, Simoni M, Nofer JR (2015) SKI-II&#x02013;a sphingosine kinase 1 inhibitor&#x02013;exacerbates atherosclerosis in low-density lipoprotein receptor-deficient (LDL-R-/-) mice on high cholesterol diet. Atherosclerosis 240(1):212&#x02013;215<pub-id pub-id-type="pmid">25801013</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR56"><label>56.</label><citation-alternatives><element-citation id="ec-CR56" publication-type="journal"><person-group person-group-type="author"><name><surname>Proudfoot</surname><given-names>D</given-names></name><name><surname>Skepper</surname><given-names>JN</given-names></name><name><surname>Hegyi</surname><given-names>L</given-names></name><name><surname>Bennett</surname><given-names>MR</given-names></name><name><surname>Shanahan</surname><given-names>CM</given-names></name><name><surname>Weissberg</surname><given-names>PL</given-names></name></person-group><article-title>Apoptosis regulates human vascular calcification in vitro: evidence for initiation of vascular calcification by apoptotic bodies</article-title><source>Circ Res</source><year>2000</year><volume>87</volume><issue>11</issue><fpage>1055</fpage><lpage>1062</lpage><pub-id pub-id-type="doi">10.1161/01.RES.87.11.1055</pub-id><pub-id pub-id-type="pmid">11090552</pub-id>
</element-citation><mixed-citation id="mc-CR56" publication-type="journal">Proudfoot D, Skepper JN, Hegyi L, Bennett MR, Shanahan CM, Weissberg PL (2000) Apoptosis regulates human vascular calcification in vitro: evidence for initiation of vascular calcification by apoptotic bodies. Circ Res 87(11):1055&#x02013;1062<pub-id pub-id-type="pmid">11090552</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR57"><label>57.</label><citation-alternatives><element-citation id="ec-CR57" publication-type="journal"><person-group person-group-type="author"><name><surname>Reese</surname><given-names>L</given-names></name><name><surname>Niepmann</surname><given-names>ST</given-names></name><name><surname>Dusing</surname><given-names>P</given-names></name><name><surname>Hanschke</surname><given-names>L</given-names></name><name><surname>Beiert</surname><given-names>T</given-names></name><name><surname>Zimmer</surname><given-names>S</given-names></name><etal/></person-group><article-title>Loss of ceramide synthase 5 inhibits the development of experimentally induced aortic valve stenosis</article-title><source>Acta Physiol (Oxf)</source><year>2024</year><volume>240</volume><issue>5</issue><fpage>e14140</fpage><pub-id pub-id-type="doi">10.1111/apha.14140</pub-id><pub-id pub-id-type="pmid">38546351</pub-id>
</element-citation><mixed-citation id="mc-CR57" publication-type="journal">Reese L, Niepmann ST, Dusing P, Hanschke L, Beiert T, Zimmer S et al (2024) Loss of ceramide synthase 5 inhibits the development of experimentally induced aortic valve stenosis. Acta Physiol (Oxf) 240(5):e14140<pub-id pub-id-type="pmid">38546351</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR58"><label>58.</label><citation-alternatives><element-citation id="ec-CR58" publication-type="journal"><person-group person-group-type="author"><name><surname>Reynolds</surname><given-names>JL</given-names></name><name><surname>Joannides</surname><given-names>AJ</given-names></name><name><surname>Skepper</surname><given-names>JN</given-names></name><name><surname>McNair</surname><given-names>R</given-names></name><name><surname>Schurgers</surname><given-names>LJ</given-names></name><name><surname>Proudfoot</surname><given-names>D</given-names></name><etal/></person-group><article-title>Human vascular smooth muscle cells undergo vesicle-mediated calcification in response to changes in extracellular calcium and phosphate concentrations: a potential mechanism for accelerated vascular calcification in ESRD</article-title><source>J Am Soc Nephrol</source><year>2004</year><volume>15</volume><issue>11</issue><fpage>2857</fpage><lpage>2867</lpage><pub-id pub-id-type="doi">10.1097/01.ASN.0000141960.01035.28</pub-id><pub-id pub-id-type="pmid">15504939</pub-id>
</element-citation><mixed-citation id="mc-CR58" publication-type="journal">Reynolds JL, Joannides AJ, Skepper JN, McNair R, Schurgers LJ, Proudfoot D et al (2004) Human vascular smooth muscle cells undergo vesicle-mediated calcification in response to changes in extracellular calcium and phosphate concentrations: a potential mechanism for accelerated vascular calcification in ESRD. J Am Soc Nephrol 15(11):2857&#x02013;2867<pub-id pub-id-type="pmid">15504939</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR59"><label>59.</label><citation-alternatives><element-citation id="ec-CR59" publication-type="journal"><person-group person-group-type="author"><name><surname>Salomone</surname><given-names>S</given-names></name><name><surname>Soydan</surname><given-names>G</given-names></name><name><surname>Ip</surname><given-names>PC</given-names></name><name><surname>Hopson</surname><given-names>KM</given-names></name><name><surname>Waeber</surname><given-names>C</given-names></name></person-group><article-title>Vessel-specific role of sphingosine kinase 1 in the vasoconstriction of isolated basilar arteries</article-title><source>Pharmacol Res</source><year>2010</year><volume>62</volume><issue>6</issue><fpage>465</fpage><lpage>474</lpage><pub-id pub-id-type="doi">10.1016/j.phrs.2010.09.002</pub-id><pub-id pub-id-type="pmid">20850539</pub-id>
</element-citation><mixed-citation id="mc-CR59" publication-type="journal">Salomone S, Soydan G, Ip PC, Hopson KM, Waeber C (2010) Vessel-specific role of sphingosine kinase 1 in the vasoconstriction of isolated basilar arteries. Pharmacol Res 62(6):465&#x02013;474<pub-id pub-id-type="pmid">20850539</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR60"><label>60.</label><citation-alternatives><element-citation id="ec-CR60" publication-type="journal"><person-group person-group-type="author"><name><surname>Sanada</surname><given-names>F</given-names></name><name><surname>Muratsu</surname><given-names>J</given-names></name><name><surname>Otsu</surname><given-names>R</given-names></name><name><surname>Shimizu</surname><given-names>H</given-names></name><name><surname>Koibuchi</surname><given-names>N</given-names></name><name><surname>Uchida</surname><given-names>K</given-names></name><etal/></person-group><article-title>Local production of activated factor X in atherosclerotic plaque induced vascular smooth muscle cell senescence</article-title><source>Sci Rep</source><year>2017</year><volume>7</volume><issue>1</issue><fpage>17172</fpage><pub-id pub-id-type="doi">10.1038/s41598-017-17508-6</pub-id><pub-id pub-id-type="pmid">29215061</pub-id>
</element-citation><mixed-citation id="mc-CR60" publication-type="journal">Sanada F, Muratsu J, Otsu R, Shimizu H, Koibuchi N, Uchida K et al (2017) Local production of activated factor X in atherosclerotic plaque induced vascular smooth muscle cell senescence. Sci Rep 7(1):17172<pub-id pub-id-type="pmid">29215061</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR61"><label>61.</label><citation-alternatives><element-citation id="ec-CR61" publication-type="journal"><person-group person-group-type="author"><name><surname>Siedlinski</surname><given-names>M</given-names></name><name><surname>Nosalski</surname><given-names>R</given-names></name><name><surname>Szczepaniak</surname><given-names>P</given-names></name><name><surname>Ludwig-Galezowska</surname><given-names>AH</given-names></name><name><surname>Mikolajczyk</surname><given-names>T</given-names></name><name><surname>Filip</surname><given-names>M</given-names></name><etal/></person-group><article-title>Vascular transcriptome profiling identifies Sphingosine kinase 1 as a modulator of angiotensin II-induced vascular dysfunction</article-title><source>Sci Rep</source><year>2017</year><volume>7</volume><fpage>44131</fpage><pub-id pub-id-type="doi">10.1038/srep44131</pub-id><pub-id pub-id-type="pmid">28276483</pub-id>
</element-citation><mixed-citation id="mc-CR61" publication-type="journal">Siedlinski M, Nosalski R, Szczepaniak P, Ludwig-Galezowska AH, Mikolajczyk T, Filip M et al (2017) Vascular transcriptome profiling identifies Sphingosine kinase 1 as a modulator of angiotensin II-induced vascular dysfunction. Sci Rep 7:44131<pub-id pub-id-type="pmid">28276483</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR62"><label>62.</label><citation-alternatives><element-citation id="ec-CR62" publication-type="journal"><person-group person-group-type="author"><name><surname>Strub</surname><given-names>GM</given-names></name><name><surname>Maceyka</surname><given-names>M</given-names></name><name><surname>Hait</surname><given-names>NC</given-names></name><name><surname>Milstien</surname><given-names>S</given-names></name><name><surname>Spiegel</surname><given-names>S</given-names></name></person-group><article-title>Extracellular and intracellular actions of sphingosine-1-phosphate</article-title><source>Adv Exp Med Biol</source><year>2010</year><volume>688</volume><fpage>141</fpage><lpage>155</lpage><pub-id pub-id-type="doi">10.1007/978-1-4419-6741-1_10</pub-id><pub-id pub-id-type="pmid">20919652</pub-id>
</element-citation><mixed-citation id="mc-CR62" publication-type="journal">Strub GM, Maceyka M, Hait NC, Milstien S, Spiegel S (2010) Extracellular and intracellular actions of sphingosine-1-phosphate. Adv Exp Med Biol 688:141&#x02013;155<pub-id pub-id-type="pmid">20919652</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR63"><label>63.</label><citation-alternatives><element-citation id="ec-CR63" publication-type="journal"><person-group person-group-type="author"><name><surname>Strub</surname><given-names>GM</given-names></name><name><surname>Paillard</surname><given-names>M</given-names></name><name><surname>Liang</surname><given-names>J</given-names></name><name><surname>Gomez</surname><given-names>L</given-names></name><name><surname>Allegood</surname><given-names>JC</given-names></name><name><surname>Hait</surname><given-names>NC</given-names></name><etal/></person-group><article-title>Sphingosine-1-phosphate produced by sphingosine kinase 2 in mitochondria interacts with prohibitin 2 to regulate complex IV assembly and respiration</article-title><source>Faseb J</source><year>2011</year><volume>25</volume><issue>2</issue><fpage>600</fpage><lpage>612</lpage><pub-id pub-id-type="doi">10.1096/fj.10-167502</pub-id><pub-id pub-id-type="pmid">20959514</pub-id>
</element-citation><mixed-citation id="mc-CR63" publication-type="journal">Strub GM, Paillard M, Liang J, Gomez L, Allegood JC, Hait NC et al (2011) Sphingosine-1-phosphate produced by sphingosine kinase 2 in mitochondria interacts with prohibitin 2 to regulate complex IV assembly and respiration. Faseb J 25(2):600&#x02013;612<pub-id pub-id-type="pmid">20959514</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR64"><label>64.</label><citation-alternatives><element-citation id="ec-CR64" publication-type="journal"><person-group person-group-type="author"><name><surname>Tanaka</surname><given-names>S</given-names></name><name><surname>Zheng</surname><given-names>S</given-names></name><name><surname>Kharel</surname><given-names>Y</given-names></name><name><surname>Fritzemeier</surname><given-names>RG</given-names></name><name><surname>Huang</surname><given-names>T</given-names></name><name><surname>Foster</surname><given-names>D</given-names></name><etal/></person-group><article-title>Sphingosine 1-phosphate signaling in perivascular cells enhances inflammation and fibrosis in the kidney</article-title><source>Sci Transl Med</source><year>2022</year><volume>14</volume><issue>658</issue><fpage>eabj2681</fpage><pub-id pub-id-type="doi">10.1126/scitranslmed.abj2681</pub-id><pub-id pub-id-type="pmid">35976996</pub-id>
</element-citation><mixed-citation id="mc-CR64" publication-type="journal">Tanaka S, Zheng S, Kharel Y, Fritzemeier RG, Huang T, Foster D et al (2022) Sphingosine 1-phosphate signaling in perivascular cells enhances inflammation and fibrosis in the kidney. Sci Transl Med 14(658):eabj2681<pub-id pub-id-type="pmid">35976996</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR65"><label>65.</label><citation-alternatives><element-citation id="ec-CR65" publication-type="journal"><person-group person-group-type="author"><name><surname>Tani</surname><given-names>T</given-names></name><name><surname>Fujiwara</surname><given-names>M</given-names></name><name><surname>Orimo</surname><given-names>H</given-names></name><name><surname>Shimizu</surname><given-names>A</given-names></name><name><surname>Narisawa</surname><given-names>S</given-names></name><name><surname>Pinkerton</surname><given-names>AB</given-names></name><etal/></person-group><article-title>Inhibition of tissue-nonspecific alkaline phosphatase protects against medial arterial calcification and improves survival probability in the CKD-MBD mouse model</article-title><source>J Pathol</source><year>2020</year><volume>250</volume><issue>1</issue><fpage>30</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1002/path.5346</pub-id><pub-id pub-id-type="pmid">31509234</pub-id>
</element-citation><mixed-citation id="mc-CR65" publication-type="journal">Tani T, Fujiwara M, Orimo H, Shimizu A, Narisawa S, Pinkerton AB et al (2020) Inhibition of tissue-nonspecific alkaline phosphatase protects against medial arterial calcification and improves survival probability in the CKD-MBD mouse model. J Pathol 250(1):30&#x02013;41<pub-id pub-id-type="pmid">31509234</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR66"><label>66.</label><citation-alternatives><element-citation id="ec-CR66" publication-type="journal"><person-group person-group-type="author"><name><surname>Van den Bergh</surname><given-names>G</given-names></name><name><surname>Van den Branden</surname><given-names>A</given-names></name><name><surname>Opdebeeck</surname><given-names>B</given-names></name><name><surname>Fransen</surname><given-names>P</given-names></name><name><surname>Neven</surname><given-names>E</given-names></name><name><surname>De Meyer</surname><given-names>GRY</given-names></name><etal/></person-group><article-title>Endothelial dysfunction aggravates arterial media calcification in warfarin administered rats</article-title><source>FASEB J</source><year>2022</year><volume>36</volume><issue>5</issue><fpage>e22315</fpage><pub-id pub-id-type="pmid">35429059</pub-id>
</element-citation><mixed-citation id="mc-CR66" publication-type="journal">Van den Bergh G, Van den Branden A, Opdebeeck B, Fransen P, Neven E, De Meyer GRY et al (2022) Endothelial dysfunction aggravates arterial media calcification in warfarin administered rats. FASEB J 36(5):e22315<pub-id pub-id-type="pmid">35429059</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR67"><label>67.</label><citation-alternatives><element-citation id="ec-CR67" publication-type="journal"><person-group person-group-type="author"><name><surname>Villa-Bellosta</surname><given-names>R</given-names></name></person-group><article-title>Role of the extracellular ATP/pyrophosphate metabolism cycle in vascular calcification</article-title><source>Purinergic Signal</source><year>2023</year><volume>19</volume><issue>2</issue><fpage>345</fpage><lpage>352</lpage><pub-id pub-id-type="doi">10.1007/s11302-022-09867-1</pub-id><pub-id pub-id-type="pmid">35511317</pub-id>
</element-citation><mixed-citation id="mc-CR67" publication-type="journal">Villa-Bellosta R (2023) Role of the extracellular ATP/pyrophosphate metabolism cycle in vascular calcification. Purinergic Signal 19(2):345&#x02013;352<pub-id pub-id-type="pmid">35511317</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR68"><label>68.</label><citation-alternatives><element-citation id="ec-CR68" publication-type="journal"><person-group person-group-type="author"><name><surname>Villa-Bellosta</surname><given-names>R</given-names></name><name><surname>Levi</surname><given-names>M</given-names></name><name><surname>Sorribas</surname><given-names>V</given-names></name></person-group><article-title>Vascular smooth muscle cell calcification and SLC20 inorganic phosphate transporters: effects of PDGF, TNF-alpha, and Pi</article-title><source>Pflugers Arch</source><year>2009</year><volume>458</volume><issue>6</issue><fpage>1151</fpage><lpage>1161</lpage><pub-id pub-id-type="doi">10.1007/s00424-009-0688-5</pub-id><pub-id pub-id-type="pmid">19506901</pub-id>
</element-citation><mixed-citation id="mc-CR68" publication-type="journal">Villa-Bellosta R, Levi M, Sorribas V (2009) Vascular smooth muscle cell calcification and SLC20 inorganic phosphate transporters: effects of PDGF, TNF-alpha, and Pi. Pflugers Arch 458(6):1151&#x02013;1161<pub-id pub-id-type="pmid">19506901</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR69"><label>69.</label><citation-alternatives><element-citation id="ec-CR69" publication-type="journal"><person-group person-group-type="author"><name><surname>Voelkl</surname><given-names>J</given-names></name><name><surname>Luong</surname><given-names>TT</given-names></name><name><surname>Tuffaha</surname><given-names>R</given-names></name><name><surname>Musculus</surname><given-names>K</given-names></name><name><surname>Auer</surname><given-names>T</given-names></name><name><surname>Lian</surname><given-names>X</given-names></name><etal/></person-group><article-title>SGK1 induces vascular smooth muscle cell calcification through NF-kappaB signaling</article-title><source>J Clin Invest</source><year>2018</year><volume>128</volume><issue>7</issue><fpage>3024</fpage><lpage>3040</lpage><pub-id pub-id-type="doi">10.1172/JCI96477</pub-id><pub-id pub-id-type="pmid">29889103</pub-id>
</element-citation><mixed-citation id="mc-CR69" publication-type="journal">Voelkl J, Luong TT, Tuffaha R, Musculus K, Auer T, Lian X et al (2018) SGK1 induces vascular smooth muscle cell calcification through NF-kappaB signaling. J Clin Invest 128(7):3024&#x02013;3040<pub-id pub-id-type="pmid">29889103</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR70"><label>70.</label><citation-alternatives><element-citation id="ec-CR70" publication-type="journal"><person-group person-group-type="author"><name><surname>Voelkl</surname><given-names>J</given-names></name><name><surname>Cejka</surname><given-names>D</given-names></name><name><surname>Alesutan</surname><given-names>I</given-names></name></person-group><article-title>An overview of the mechanisms in vascular calcification during chronic kidney disease</article-title><source>Curr Opin Nephrol Hypertens</source><year>2019</year><volume>28</volume><issue>4</issue><fpage>289</fpage><lpage>296</lpage><pub-id pub-id-type="doi">10.1097/MNH.0000000000000507</pub-id><pub-id pub-id-type="pmid">30985336</pub-id>
</element-citation><mixed-citation id="mc-CR70" publication-type="journal">Voelkl J, Cejka D, Alesutan I (2019) An overview of the mechanisms in vascular calcification during chronic kidney disease. Curr Opin Nephrol Hypertens 28(4):289&#x02013;296<pub-id pub-id-type="pmid">30985336</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR71"><label>71.</label><citation-alternatives><element-citation id="ec-CR71" publication-type="journal"><person-group person-group-type="author"><name><surname>Voelkl</surname><given-names>J</given-names></name><name><surname>Egli-Spichtig</surname><given-names>D</given-names></name><name><surname>Alesutan</surname><given-names>I</given-names></name><name><surname>Wagner</surname><given-names>CA</given-names></name></person-group><article-title>Inflammation: a putative link between phosphate metabolism and cardiovascular disease</article-title><source>Clin Sci (Lond)</source><year>2021</year><volume>135</volume><issue>1</issue><fpage>201</fpage><lpage>227</lpage><pub-id pub-id-type="doi">10.1042/CS20190895</pub-id><pub-id pub-id-type="pmid">33416083</pub-id>
</element-citation><mixed-citation id="mc-CR71" publication-type="journal">Voelkl J, Egli-Spichtig D, Alesutan I, Wagner CA (2021) Inflammation: a putative link between phosphate metabolism and cardiovascular disease. Clin Sci (Lond) 135(1):201&#x02013;227<pub-id pub-id-type="pmid">33416083</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR72"><label>72.</label><citation-alternatives><element-citation id="ec-CR72" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Seed</surname><given-names>B</given-names></name></person-group><article-title>A PCR primer bank for quantitative gene expression analysis</article-title><source>Nucleic Acids Res</source><year>2003</year><volume>31</volume><issue>24</issue><fpage>e154</fpage><pub-id pub-id-type="doi">10.1093/nar/gng154</pub-id><pub-id pub-id-type="pmid">14654707</pub-id>
</element-citation><mixed-citation id="mc-CR72" publication-type="journal">Wang X, Seed B (2003) A PCR primer bank for quantitative gene expression analysis. Nucleic Acids Res 31(24):e154<pub-id pub-id-type="pmid">14654707</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR73"><label>73.</label><citation-alternatives><element-citation id="ec-CR73" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>N</given-names></name><name><surname>Li</surname><given-names>JY</given-names></name><name><surname>Zeng</surname><given-names>B</given-names></name><name><surname>Chen</surname><given-names>GL</given-names></name></person-group><article-title>Sphingosine-1-phosphate signaling in cardiovascular diseases</article-title><source>Biomolecules</source><year>2023</year><volume>13</volume><issue>5</issue><fpage>818</fpage><pub-id pub-id-type="doi">10.3390/biom13050818</pub-id><pub-id pub-id-type="pmid">37238688</pub-id>
</element-citation><mixed-citation id="mc-CR73" publication-type="journal">Wang N, Li JY, Zeng B, Chen GL (2023) Sphingosine-1-phosphate signaling in cardiovascular diseases. Biomolecules 13(5):818<pub-id pub-id-type="pmid">37238688</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR74"><label>74.</label><citation-alternatives><element-citation id="ec-CR74" publication-type="journal"><person-group person-group-type="author"><name><surname>Xiao</surname><given-names>Y</given-names></name><name><surname>Ma</surname><given-names>D</given-names></name><name><surname>Yang</surname><given-names>YS</given-names></name><name><surname>Yang</surname><given-names>F</given-names></name><name><surname>Ding</surname><given-names>JH</given-names></name><name><surname>Gong</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Comprehensive metabolomics expands precision medicine for triple-negative breast cancer</article-title><source>Cell Res</source><year>2022</year><volume>32</volume><issue>5</issue><fpage>477</fpage><lpage>490</lpage><pub-id pub-id-type="doi">10.1038/s41422-022-00614-0</pub-id><pub-id pub-id-type="pmid">35105939</pub-id>
</element-citation><mixed-citation id="mc-CR74" publication-type="journal">Xiao Y, Ma D, Yang YS, Yang F, Ding JH, Gong Y et al (2022) Comprehensive metabolomics expands precision medicine for triple-negative breast cancer. Cell Res 32(5):477&#x02013;490<pub-id pub-id-type="pmid">35105939</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR75"><label>75.</label><citation-alternatives><element-citation id="ec-CR75" publication-type="journal"><person-group person-group-type="author"><name><surname>Xiao</surname><given-names>S</given-names></name><name><surname>Peng</surname><given-names>K</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Long</surname><given-names>Y</given-names></name><name><surname>Yu</surname><given-names>Q</given-names></name></person-group><article-title>The role of sphingosine-1-phosphate in autophagy and related disorders</article-title><source>Cell Death Discov</source><year>2023</year><volume>9</volume><issue>1</issue><fpage>380</fpage><pub-id pub-id-type="doi">10.1038/s41420-023-01681-x</pub-id><pub-id pub-id-type="pmid">37852968</pub-id>
</element-citation><mixed-citation id="mc-CR75" publication-type="journal">Xiao S, Peng K, Li C, Long Y, Yu Q (2023) The role of sphingosine-1-phosphate in autophagy and related disorders. Cell Death Discov 9(1):380<pub-id pub-id-type="pmid">37852968</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR76"><label>76.</label><citation-alternatives><element-citation id="ec-CR76" publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>F</given-names></name><name><surname>Mai</surname><given-names>P</given-names></name><name><surname>Peng</surname><given-names>Y</given-names></name><name><surname>Shu</surname><given-names>X</given-names></name><name><surname>Nie</surname><given-names>R</given-names></name><etal/></person-group><article-title>Mechanism analysis of vascular calcification based on fluid dynamics</article-title><source>Diagnostics (Basel)</source><year>2023</year><volume>13</volume><issue>16</issue><fpage>2632</fpage><pub-id pub-id-type="doi">10.3390/diagnostics13162632</pub-id><pub-id pub-id-type="pmid">37627891</pub-id>
</element-citation><mixed-citation id="mc-CR76" publication-type="journal">Xu S, Wang F, Mai P, Peng Y, Shu X, Nie R et al (2023) Mechanism analysis of vascular calcification based on fluid dynamics. Diagnostics (Basel) 13(16):2632<pub-id pub-id-type="pmid">37627891</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR77"><label>77.</label><citation-alternatives><element-citation id="ec-CR77" publication-type="journal"><person-group person-group-type="author"><name><surname>You</surname><given-names>B</given-names></name><name><surname>Ren</surname><given-names>A</given-names></name><name><surname>Yan</surname><given-names>G</given-names></name><name><surname>Sun</surname><given-names>J</given-names></name></person-group><article-title>Activation of sphingosine kinase-1 mediates inhibition of vascular smooth muscle cell apoptosis by hyperglycemia</article-title><source>Diabetes</source><year>2007</year><volume>56</volume><issue>5</issue><fpage>1445</fpage><lpage>1453</lpage><pub-id pub-id-type="doi">10.2337/db06-1418</pub-id><pub-id pub-id-type="pmid">17325258</pub-id>
</element-citation><mixed-citation id="mc-CR77" publication-type="journal">You B, Ren A, Yan G, Sun J (2007) Activation of sphingosine kinase-1 mediates inhibition of vascular smooth muscle cell apoptosis by hyperglycemia. Diabetes 56(5):1445&#x02013;1453<pub-id pub-id-type="pmid">17325258</pub-id>
</mixed-citation></citation-alternatives></ref></ref-list></back></article>